RNEC Number,EudraCT Number,Protocol Number,Type of Study,Sponsor's Name,Title of the trial,Recruitment Status,Date of Global End,Infarmed Authorization Date,CEC Opinion Date,Non-technical title,Paediatric Investigation Plan,Medical condition(s),Therapeutic Confirmatory (Phase II),Therapeutic Confirmatory (Phase III),Therapeutic Confirmatory (Phase IV),Age_Range,Gender
181,2016-004740-11,MK-3475-522,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)",Active,,20/03/2017,21/03/2017,"A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)",No,Neoadjuvant and adjuvant treatment for locally-advanced TNBC,,Yes,,"Adult , Elderly","Female , Male"
221,2016-002744-17,MA39189,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD",Active,,07/04/2017,28/07/2017,A Study of Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease,No,Fibrosing interstitial lung disease (ILD) of unknown origin,Yes,,,"Adult , Elderly","Female , Male"
241,2011-005249-12,EFC11759,Interventional studies with investigational medicinal products,Genzyme Corporation,"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension",Not Commenced,,08/03/2017,28/04/2017,"Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis",Yes,Multiple Sclerosis,,Yes,,Under 18,"Female , Male"
302,2015-004477-32,CAIN457F2366,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis",Ended,,19/04/2017,26/04/2017,Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis,No,Psoriatic Arthritis,,Yes,,"Adult , Elderly","Female , Male"
721,2016-004015-13,FMD-TRI-2016-01,Interventional studies with investigational medicinal products,Ferrer Internacional S.A,"A phase III, international, multicenter, randomized and open label study to evaluate the efficacy on LDLc and blood pressure reduction and safety of Trinomia® versus usual care in patients with very high cardiovascular risk without previous cardiovascular event. The VULCANO trial",Active,,28/04/2017,05/06/2017,Clinical study to evaluate the efficacy on cholesterol and blood pressure reduction and safety of Trinomia® versus usual care in patients with very high cardiovascular risk without previous cardiovascular event.,No,Very high cardiovascular risk without previous cardiovascular event,,Yes,,"Adult , Elderly","Female , Male"
741,2014-002632-14,ODYSSEY(PENTA20),Interventional studies with investigational medicinal products,Fondazione PENTA ONLUS,A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART.,Active,,15/05/2017,24/07/2017,A randomised trial of dolutegravir (DTG)-based antiretroviral treatment vs standard of care (SOC) in children with HIV infection starting first treatment or switching to second-line antiretrovirals.,No,Paediatric HIV infection,Yes,Yes,,Under 18,"Female , Male"
761,2016-003093-40,FADOI_032016,Interventional studies with investigational medicinal products,FONDAZIONE FADOI,"Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study - the Caravaggio study 
",Active,,07/06/2017,30/06/2017,Apixaban for the treatment of venous thromboembolism in patients with cancer,No,Venous thromboembolism in cancer patients ,,Yes,,"Adult , Elderly","Female , Male"
781,2013-000267-84,CSOM230B2412,Interventional studies with investigational medicinal products,Novartis Pharma AG,"An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment",Not Commenced,,07/04/2017,26/04/2017,Study to roll over patients who have completed a study with pasireotide and benefit from the study treatment.,No,"Cushing's disease
Acromegaly 
Carcinoid tumors
Rare tumors of neuroendocrine origin
Dumping Syndrome
Metastatic melanoma 
Metastatic Merkel cell carcinoma ",,,Yes,"Adult , Elderly","Female , Male"
801,2015-001924-40,GED-0301-CD-003,Interventional studies with investigational medicinal products,"CELGENE, SOCIEDADE UNIPESSOAL, LDA.","A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with active Crohn¿s disease",Not Commenced,,29/05/2017,26/06/2017,A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn's disease in adults and adolescents. ,No,Active Crohn's disease  ,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
821,2016-003202-14,PCYC-1141-CA,Interventional studies with investigational medicinal products,Pharmacyclics LLC,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton¿s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma",Active,,17/05/2017,15/05/2017,"A Clinical Study of Rituximab with Ibrutinib Compared to Rituxumab Alone, and Subsequently of Ibrutinib Alone Compared to Placebo in Treatment Naïve Subjects with Follicular Lymphoma",No,Follicular lymphoma,,Yes,,"Adult , Elderly","Female , Male"
841,2016-003903-79,SYL1001_IV,Interventional studies with investigational medicinal products,Sylentis SAU - Pharma Mar Group,A double-masked study of SYL1001 in patients with moderate to severe dry eye disease (DED),Not Commenced,,02/05/2017,24/07/2017,A double-masked study of SYL1001 in patients with moderate to severe dry eye disease,No,Moderate to severe dry eye disease (DED),,Yes,,"Adult , Elderly","Female , Male"
861,2016-003288-20,BN29553,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER¿S DISEASE",Not Commenced,,27/04/2017,08/05/2017,An Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer¿s Disease,No,Alzheimer¿s Disease,,Yes,,"Adult , Elderly","Female , Male"
881,2014-003277-42,MCLA-128-CL01,Interventional studies with investigational medicinal products,Merus N.V.,"A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",Not Commenced,,03/08/2017,09/10/2017,"A study of the investigational drug MCLA-128 which is an antibody that is
specific to both HER2 and HER3 receptors that are associated with solid
tumors",No,Solid Tumors,Yes,,,"Adult , Elderly","Female , Male"
941,2016-003292-22,CVAY736A2201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren¿s Syndrome",Ended,,11/05/2017,09/06/2017,Study of safety and efficacy of VAY736 in patients with primary Sjogren¿s Syndrome (pSS),No,Primary Sjogren¿s syndrome,Yes,,,"Adult , Elderly","Female , Male"
981,2016-001466-28,M15-656,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy",Ended,,23/05/2017,18/09/2017,A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy,No,Acute Myeloid Leukemia,,Yes,,"Adult , Elderly","Female , Male"
1001,2016-004566-26,3152-301-002,Interventional studies with investigational medicinal products,"Tobira Therapeutics, Inc., a subsidary of Allergan plc","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis ",Ended,,26/05/2017,13/09/2017,"The study of an investigational drug, Cenicriviroc, for the treatment of liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).",No,Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis,,Yes,,"Adult , Elderly","Female , Male"
1002,2012-001091-11,BIA-2093-211,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZURES AGED FROM 1 MONTH TO <2 YEARS",Not Commenced,,30/06/2017,28/08/2017,"Clinical Trial to investigate the bioavailability, safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures",Yes,refractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 years,Yes,,,Under 18,"Female , Male"
1021,2016-001072-29,BIA-2093-211/EXT,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZURES AGED FROM 1 MONTH TO <2 YEARS ¿ 1-YEAR EXTENSION",Not Commenced,,30/06/2017,28/08/2017,"Clinical Trial to investigate the safety and tolerability of
Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures for one year",Yes,"refractory epilepsy with partial-onset seizures in children aged from 1
month to < 2 years",Yes,,,Under 18,"Female , Male"
1041,2015-001088-38,BAY80-6946/17833,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin¿s lymphoma (iNHL) - CHRONOS-4",Ended,,05/05/2017,19/01/2018,A study investigating copanlisib in combination with standard treatment versus standard treatment alone in order to see if copanlisib improves the response to standard treatment in patients with relapsed indolent non-Hodgkin's lymphoma.,No,Patients with relapsed indolent non-Hodgkin's lymphoma,,Yes,,"Adult , Elderly","Female , Male"
1061,2016-003866-14,B5091007,Interventional studies with investigational medicinal products,PFIZER INC,"A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older",Ended,,07/07/2017,26/06/2017,"A study to assess whether a vaccine against Clostridium difficile prevents the disease, and whether it is safe and well tolerated when given to adults 50 years of age and older",No,Primary C difficile infection (CDI) ,,Yes,,"Adult , Elderly","Female , Male"
1081,2016-002453-38,15-102-14,Interventional studies with investigational medicinal products,Nektar Therapeutics,"A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician¿s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine",Ended,,25/05/2017,24/08/2017,A study to compare the study drug NKTR-102 with standard treatments in breast cancer patients with stable brain metastases ,No,Metastatic breast cancer with stable brain metastases,,Yes,,"Adult , Elderly","Female , Male"
1141,2016-004062-26,BAY1067197/17582,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction",,,21/06/2017,26/06/2017,PANACHE - A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with preserved ejection fraction ,No,chronic heart failure with preserved ejection fraction (LVEF equal or above 45%),Yes,,,"Adult , Elderly","Female , Male"
1142,2016-003410-28,CLCZ696D2302,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction",Ended,,25/05/2017,05/06/2017,Study to evaluate the effect of LCZ696 compared to individualized medical therapy for comorbidities in Heart Failure with preserved Ejection Fraction (HFpEF) patients,No,Heart Failure with preserved Ejection Fraction (HFpEF),,Yes,,"Adult , Elderly","Female , Male"
1181,2015-002743-33,Z7224L01,Interventional studies with investigational medicinal products,Zambon SpA,"A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)",Ended,,13/07/2017,05/06/2017,"A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)",No,Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa ,,Yes,,"Adult , Elderly","Female , Male"
1281,2017-000549-38,LIP-01-01,Interventional studies with investigational medicinal products,Laboratorios Ojer Pharma S.L,An open-label study to investigate the local tolerability and acceptability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis,,,29/12/2017,29/01/2018,An open-label study to investigate the local tolerability and acceptability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis,No,Herpes labialis,,,Yes,"Adult , Elderly","Female , Male"
1301,2016-002937-31,MA30143,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis ",Active,,05/07/2017,24/07/2017,A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis,No,Relapsing remitting multiple sclerosis (RRMS),,Yes,,Adult,"Female , Male"
1321,2016-004429-17,CO39303,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER",Ended,,04/05/2017,24/08/2017,"A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer",No,Metastatic Castrate-Resistant Prostate Cancer,,Yes,,"Adult , Elderly",Male
1341,2016-004128-42,E2609-G000-302,Interventional studies with investigational medicinal products,Eisai Limited,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer¿s Disease",Ended,,04/07/2017,18/09/2017,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer¿s Disease",No,Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD,,Yes,,"Adult , Elderly","Female , Male"
1381,2016-004374-18,GS-US-384-1943,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.",Ended,,17/05/2017,22/09/2017,"A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.",No,Nonalcoholic Steatohepatitis (NASH),,Yes,,"Adult , Elderly","Female , Male"
1382,2016-004148-13,GS-US-384-1944,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)",Not Commenced,,17/05/2017,22/09/2017,"A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)",No,Nonalcoholic Steatohepatitis (NASH),,Yes,,"Adult , Elderly","Female , Male"
1401,2016-002629-13,CY4033,Interventional studies with investigational medicinal products,"Cytokinetics, Inc.","A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031)",,,12/07/2017,28/08/2017,An Open-Label Extension Study for Patients Who Completed VITALITY-ALS (CY 4031),No,Amyotrophic Lateral Sclerosis (ALS),,Yes,,"Adult , Elderly","Female , Male"
1421,2016-002794-35,CPDR001F2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib
and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma",Ended,,24/08/2017,30/10/2017,"Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in patients with a genetically distinct subtype of unresectable or metastatic melanoma, which is characterised by a mutation in the BRAF gene  ",No,Unresectable or metastatic BRAF V600 mutant melanoma,,Yes,,"Adult , Elderly","Female , Male"
1441,2016-004648-12,CLS1003-301,Interventional studies with investigational medicinal products,"Clearside Biomedical, Inc.","SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION",Active,,29/09/2017,09/10/2017,"this is a phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO",No,Retinal Vein Occlusion,,Yes,,Adult,"Female , Male"
1463,2016-002778-11,E7080-G000-218,Interventional studies with investigational medicinal products,Eisai Limited,"A Randomized, Open-label (formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment",Active,,30/05/2017,07/05/2019,"A Randomized, Open-label (formerly Double-Blind), Phase 2 Trial to investigate how safe and how efficacious  Lenvatinib  is at two different starting doses (18 mg vs. 14 mg QD) when it is given in Combination with Everolimus (5 mg once a day ) in patients with  Renal cancer that have already had one VEGF-Targeted Treatment",No,Advanced renal cell carcinoma,Yes,,,"Adult , Elderly","Female , Male"
1501,2015-003910-26,01/2015,Interventional studies with investigational medicinal products,Núcleo de Estudos de Hipertensão da Beira Interior,"Fase II, unicenter, open, randomized trial to evaluate the response of Th17 and T regulatory lymphocytes to 24 weeks supplementation with cholecalciferol in patients with arterial hypertension, obesity and vitamin D deficiency. ",Not Commenced,,18/07/2017,11/12/2017,"Effects of cholecalciferol supplementation in peripheral blood leucocytes in patients with arterial hypertension, obesity and vitamin D deficiency.",No,"Obesity associated arterial hypertension
Metabolic syndrome associated arterial hypertension",Yes,,,Adult,"Female , Male"
1521,2016-002855-48,BAY1002670/15789,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids",Active,,31/07/2017,28/08/2017,Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroids,No,Leiomyoma,,Yes,,Adult,Female
1621,2017-000657-39,0217/DEV,Interventional studies with investigational medicinal products,Develco Pharma Schweiz AG,"Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid induced constipation",Ended,,19/07/2017,28/08/2017,"Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.",No,Opioid induced constipation,,Yes,,"Adult , Elderly","Female , Male"
1641,2016-005230-30,SPX-101-CF-201,Interventional studies with investigational medicinal products,"Spyryx Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects with Cystic Fibrosis (HOPE-1 STUDY: HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS)",Active,,04/08/2017,28/08/2017, A research study to find out if SPX-101 helps people with Cystic Fibrosis and to find out if it is safe.,No,Cystic Fibrosis,Yes,,,Adult,"Female , Male"
1681,2016-004967-38,M16-135,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis",Ended,,08/06/2017,18/09/2017,"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis",No,HCV,,Yes,,"Adult , Elderly","Female , Male"
1741,2016-004359-57,CanStem111P,Interventional studies with investigational medicinal products,"Sumitomo Dainippon Pharma Oncology, Inc",A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.,Ended,,29/08/2017,30/10/2017,"The aim of this study is to see how well an investigational drug (called
BBI-608) works when it is given in combination with a standard anticancer
treatment for people with advanced pancreatic cancer.",No,This study will enroll patients with histologically or cytologically confirmed adenocarcinoma of the pancreas that is metastatic (Stage IV). ,,Yes,,"Adult , Elderly","Female , Male"
1781,2016-003123-32,M16-006,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease",Active,,20/07/2017,02/10/2017,A Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease,No,Crohn's Disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
1782,2016-003190-17,M15-991,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",Active,,20/07/2017,02/10/2017,A Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease.,No,Crohn's disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
1783,2016-003191-50,M16-000,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
",Ended,,20/07/2017,02/10/2017,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
",No,Crohn's disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
1841,2016-001224-63,CNTO1959PSA3002,Interventional studies with investigational medicinal products,"Janssen-Cilag Farmacêutica, Lda.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis",,,17/10/2017,27/12/2017,A Phase 3 Study of Guselkumab in Subjects with Active Psoriatic Arthritis,No,Active Psoriatic Arthritis,,Yes,,"Adult , Elderly","Female , Male"
1861,2015-003166-91,CETB115E2201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia.",Ended,,15/12/2017,23/08/2018,"A phase II dose-escalation study characterizing the PK of eltrombopag in pediatric patients with previously untreated or relapsed severe aplastic anemia or recurrent aplastic anemia.
",Yes,"Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA)",Yes,,,Under 18,"Female , Male"
1881,2017-000070-11,MK-6072-001,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal Antibody to C. difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (MODIFY III)",Active,,10/10/2017,19/01/2018,The study of Bezlotoxumab (MK-6072) versus placebo in children with Clostridium Difficile (CDI) diarrhea,Yes,Prevention of recurrent Clostridium difficile infection (CDI),,Yes,,Under 18,"Female , Male"
1901,2016-000280-16,CEMA401A2201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia",,,27/09/2017,04/12/2017,Dose response study of EMA401 in patients with post-herpetic neuralgia (PHN),No,Post-herpetic neuralgia,Yes,,,"Adult , Elderly","Female , Male"
1921,2016-004130-24,M15-572,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) ¿ SELECT ¿ PsA 1",Ended,,19/07/2017,18/09/2017,A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug,No,Moderately to Severely Active Psoriatic Arthritis,,Yes,,"Adult , Elderly","Female , Male"
1941,2016-004152-30,M15-554,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib  (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) ¿ SELECT ¿ PsA 2",Ended,,19/07/2017,18/09/2017,A Study Comparing ABT-494 to Placebo in Subjects with Psoriatic Arthritis Who Have an Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug,No,Moderately to Severely Active Psoriatic Arthritis,,Yes,,"Adult , Elderly","Female , Male"
1961,2015-004105-16,MO29872,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY",Active,,20/07/2017,18/09/2017,A Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB Not Amenable For Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,No,Non-small cell lung cancer,,Yes,,"Adult , Elderly","Female , Male"
1981,2015-002801-12,ONT-380-206,Interventional studies with investigational medicinal products,Seagen Inc.,"Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in
Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)",Active,,03/11/2017,29/01/2018,A clinical trial comparing tucatinib against placebo in patients who have advanced breast cancer and are being treated with capecitabine and trastuzamab,No,Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma,Yes,,,"Adult , Elderly","Female , Male"
2061,2017-000538-78,INCB39110-301,Interventional studies with investigational medicinal products,Incyte Biosciences UK Ltd,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease",Not Commenced,,27/07/2017,18/09/2017,A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host disease,No,"Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD",,Yes,,"Adult , Elderly","Female , Male"
2081,2014-003527-22,CINC424A2X01B,Interventional studies with investigational medicinal products,Novartis Pharma AG,"An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatment",Ended,,17/10/2017,28/08/2017,A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatment,No,This roll-over study is designed to accept patients with varied disease origins. Please refer to the parent protocol for the disease background information and rationale for use of ruxolitinib in their individual indications.,,,Yes,"Under 18 , Adult , Elderly","Female , Male"
2101,2014-002606-20,CV185-325/B0661037,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT",Not Commenced,,20/12/2017,03/05/2018,"A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT",Yes,Venous Thromboembolism,,Yes,,Under 18,"Female , Male"
2181,2016-002761-63,HPV-301,Interventional studies with investigational medicinal products,"Inovio Pharmaceuticals, Inc","A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA¿ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) OF THE CERVIX",,,11/12/2017,29/01/2018,A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).,No,HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX,,Yes,,Adult,Female
2201,2017-000431-14,M16-098,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis",Ended,,14/08/2017,09/10/2017,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis",No,Active Ankylosing Spondylitis,Yes,Yes,,"Adult , Elderly","Female , Male"
2241,2014-005012-42,747-302,Interventional studies with investigational medicinal products,Intercept Pharmaceuticals Inc,"A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis.              
The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT).

",Ended,,29/11/2017,01/02/2018,"A Phase 4 clinical trial to measure the effect of Obeticholic acid against a placebo, in conjunction with standard treatment, on selected clinical measurements in patients with the liver disease, Primary Biliary Cholangitis.
The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT).

",No,Primary Biliary Cholangitis,,,Yes,"Adult , Elderly","Female , Male"
2262,2016-001463-36,ALN-AT3SC-003,Interventional studies with investigational medicinal products,Genzyme Corporation,"ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitusiran (ALN-AT3SC) in patients with hemophilia A or B, with inhibitory antibodies to factor VIII or IX",Active,,08/05/2018,06/06/2018,A Study of fitusiran (ALN-AT3SC) in hemophilia A and B patients with inhibitors ,No,Hemophilia A or Hemophilia B,,Yes,,"Under 18 , Adult , Elderly",Male
2281,2016-001464-11,ALN-AT3SC-004,Interventional studies with investigational medicinal products,"Alnylam Pharmaceuticals, Inc.","ATLAS-A/B: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX",Active,,08/05/2018,06/06/2018,A study of fitusiran (ALN-AT3SC) in hemophilia A and B patients without inhibitors,No,Hemophilia A or Hemophilia B,,Yes,,"Under 18 , Adult , Elderly",Male
2301,2016-002584-33,CINC424C2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation 
",Ended,,13/11/2017,22/12/2017,Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation,No,corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation ,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
2321,2014-000565-47,BAY59-7939/14372,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism",,,29/01/2018,27/02/2018,Rivaroxaban for treatment in venous thrombosis in children,Yes,Venous Thrombosis,,Yes,,Under 18,"Female , Male"
2341,2016-004432-38,CINC424D2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation,Active,,13/11/2017,21/12/2017,Study of efficacy and safety of ruxolitinib vs. best available therapy (BAT) in patients with corticosteroid refractory chronic graft versus host disease after bone marrow transplantation,No,corticosteroid refractory chronic Graft vs Host Disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
2401,2017-001724-22,GA39688,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",Active,,25/01/2018,08/01/2018,A Phase 3 Clinical Trial of Omalizumab for Chronic Rhinosinusitus with Nasal Polyps,No,Chronic rhinosinusitis with nasal polyps,,Yes,,"Adult , Elderly","Female , Male"
2421,2017-002821-39,MCLA-128-CL02,Interventional studies with investigational medicinal products,Merus N.V.,Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC,Ended,,11/12/2017,02/04/2018,Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC) : with endocrine therapy for patients with presenting high expression of hormone receptors or with trastuzumab/chemotherapy for patients presenting a high expression of a specific receptor (HER2) ,No,Metastatic Breast Cancer,Yes,,,"Adult , Elderly",Female
2582,2017-001588-19,MVT-601-3101,Interventional studies with investigational medicinal products,Myovant Sciences GmbH,"SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain",Active,,05/12/2017,31/01/2018,A study to evaluate the efficacy and safety of Relugolix in Women with Endometriosis-Associated Pain,No,Endometriosis,,Yes,,Adult,Female
2601,2017-000284-32,SHP634-401,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",Active,,21/02/2018,02/04/2018,"Symptom Improvement Evaluation and Metabolic control among Adult Subjects with Symptomatic Hypoparathyroidism Treated with Recombinant
Human Parathyroid hormone [rhPTH(1-84)]
",No,Hypoparathyroidism,,Yes,Yes,"Adult , Elderly","Female , Male"
2621,2016-002976-28,CCNP520A2202J,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer¿s Disease (AD)",Ended,,12/12/2017,02/04/2018,To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer¿s Disease (AD),No,Alzheimer's disease,Yes,Yes,,"Adult , Elderly","Female , Male"
2641,2017-000905-19,Rec0/0438-IT-CL0491,Interventional studies with investigational medicinal products,Recordati Spa,"EFFECTS OF TWO DIFFERENT DOSES OF REC 0/0438  ADMINISTERED BY INTRA-VESICAL INSTILLATION IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY: A REPEATED DOSES, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY
",Not Commenced,,11/12/2017,30/01/2018,A study in male and female patients with neurogenic detrusor overactivity due to spinal cord injury to evaluate the effects of two different doses of REC 0/0438 administered by intra-vesical injection.,No,neurogenic detrusor overactivity due to spinal cord injury,Yes,,,Adult,"Female , Male"
2642,2017-002238-21,EFC12522,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant",Not Commenced,,18/12/2017,15/02/2018,"Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant ",No,Plasma cell myeloma,,Yes,,"Adult , Elderly","Female , Male"
2662,2017-002644-32,EFC14875,Interventional studies with investigational medicinal products,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function",Not Commenced,,06/03/2018,19/02/2018,"Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
",No,"Type 2 diabetes mellitus
Chronic kidney disease",,Yes,,"Adult , Elderly","Female , Male"
2701,2017-000216-42,AC-065A404,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient¿s self-reported symptoms and their impacts",Not Commenced,,28/12/2017,14/05/2018,"Daily life physical activity and disease symptoms assessed in patients with
pulmonary arterial hypertension (PAH) treated with selexipag",No,Pulmonary arterial hypertension,,,Yes,"Adult , Elderly","Female , Male"
2721,2016-002095-26,64041575RSV2002,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection,Not Commenced,,27/11/2017,19/02/2018,A long-term follow-up of study 64041575RSV2004 to investigate the effects of lumicitabine (JNJ-64041575) in infants and children with a history of Respiratory Syncytial Virus infection,No,Respiratory syncytial virus infection,Yes,,,Under 18,"Female , Male"
2761,2017-000402-38,GS-US-418-4279,Interventional studies with investigational medicinal products,Galapagos NV,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease",Ended,,13/11/2017,05/06/2018,A clinical trail to evaluate the testicular safety of Filgotinib in adult males with Moderately to Severely Active Inflammatory Bowel Disease,No,To evaluate the testicular safety of filgotinib in adult males with moderately to severely Active Inflammatory Bowel Disease,Yes,,,Adult,Male
2881,2017-002023-21,GO39942,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA",Not Commenced,,13/11/2017,20/05/2019,A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma,No,Diffuse large B-cell lymphoma (DLBCL),,Yes,,"Adult , Elderly","Female , Male"
2901,2017-003659-52,PULSE,Interventional studies with investigational medicinal products,ANTONIO MANUEL ROBALO NUNES,"Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease: an open-label, randomized, 2-arm, no treatment control, parallel study ¿ PULSE study",Not Commenced,,05/02/2018,26/06/2018,Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease,No,Chronic Obstructive Pulmonary Disease and Iron Deficiency,,,Yes,"Adult , Elderly","Female , Male"
2921,2016-000222-19,H2020-PHC-18-2015-667224,Interventional studies with investigational medicinal products,University Hospital of Tuebingen,Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome ¿ a blinded randomized placebo-controlled parallel group multicenter trial for superiority (Phase III),Not Commenced,,28/01/2019,08/11/2019,A European trial to evaluate the effect of Allopurinol administered very early after birth on brain injury in children with oxygen deficiency during birth,No,"Perinatal Asphyxia, hypoxic-ischemic brain injury",,Yes,,Under 18,"Female , Male"
2981,2016-003403-66,1199.225,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","An open-label extension trial to assess the long term safety of
nintedanib in patients with `Systemic Sclerosis associated
Interstitial Lung Disease¿ (SSc-ILD)",Ended,,23/02/2018,19/02/2018,"A trial to evaluate the safety of long term treatment with
nintedanib in patients with scleroderma related lung fibrosis.",No,Systemic Sclerosis associated Interstitial Lung Disease,,Yes,,"Adult , Elderly","Female , Male"
3041,2016-004719-10,AC-058B303,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis",Active,,02/07/2018,12/03/2018,A research study to look at the long term benefits and risks of ponesimod 20 mg treatment for patients with relapsing multiple sclerosis.,No,relapsing multiple sclerosis,,Yes,,Adult,"Female , Male"
3121,2017-000572-28,SHP647-302,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302)",Active,,13/03/2018,09/04/2018,"Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) ¿ using a randomised and blinded study design  (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 302).",Yes,Ulcerative Colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
3141,2017-000573-37,SHP647-303,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)",Active,,13/03/2018,12/03/2018,"Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) ¿ using a randomised and blinded study design  (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 303).",Yes,Ulcerative colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
3161,2017-000574-11,SHP647-304,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) 
",Active,,02/04/2018,23/04/2018,"Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)",No,Ulcerative colitis or Crohn's Disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
3221,2017-002343-14,FMD-TRI-2017-01,Interventional studies with investigational medicinal products,Ferrer Internacional S.A,"A multicentre, randomised, open-label, parallel-group trial to study the safety and non-inferiority of a new therapeutic strategy (the Fuster-CNIC-Ferrer cardiovascular polypill) versus usual care on LDLc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: The APOLO trial.",Active,,07/05/2018,23/04/2018,A trial to study a new therapeutic strategy (the Fuster-CNIC-Ferrer cardiovascular polypill) versus usual care on LDLc and blood pressure reduction in patients with atherothrombotic cardiovascular disease: The APOLO trial.,No,Patients with atherothrombotic cardiovascular disease,,Yes,,Adult,"Female , Male"
3241,2017-003288-36,COMP001,Interventional studies with investigational medicinal products,Compass Pathfinder Limited,The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD),Not Commenced,,02/10/2019,12/12/2019,The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression,No,Treatment-Resistant Depression (P-TRD),Yes,,,"Adult , Elderly","Female , Male"
3281,2015-003997-33,NOAH-AFNET6,Interventional studies with investigational medicinal products,Kompetenznetz-Vorhofflimmern e.V. (Atrial Fibrillation NETwork),Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes ,Active,,07/06/2018,25/06/2018,Administration of low risk oral anticoagulation agents to patients with pre-stage atrial fibrillation for stroke prophylaxis,No,"Atrial fibrillation (AF) is one cause of stroke.  Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compared to stroke rates in patients with diagnosed AF. 
Prevention of stroke, systemic embolism or cardiovascular death in patients with AHRE but without diagnosed atrial fibrillation (AF) and in addition at least two stroke risk factors by intake of NOACs shall be investigated.",,Yes,,Elderly,"Female , Male"
3301,2016-000669-21,1218-0091,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus.

P/0324/2016, P/0326/2016.",Active,,12/03/2018,02/04/2018,DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents (DINAMO),Yes,Diabetes Mellitus Type 2,,Yes,,Under 18,"Female , Male"
3361,2017-002767-17,D0816C00020,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy.",Active,,19/04/2018,23/04/2018,"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy",No,Non Germline BRCA Mutated Ovarian Cancer,,Yes,,"Adult , Elderly",Female
3381,2017-003851-45,CAEB1102-101A,Interventional studies with investigational medicinal products,"Aeglea Biotherapeutics, Inc.","A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102",,,02/04/2018,16/07/2018,"A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102",No,"Arginase 1 deficiency
Hyperargininemia",Yes,,,"Under 18 , Adult","Female , Male"
3401,2017-001176-31,19215,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies,,,28/02/2018,12/03/2018,"A long term follow up study to look at the progress of patients with
symptoms suggestive of MS who took part in previous studies with
Betaferon®/Betaseron®",No,Clinically-isolated syndrome (CIS) and multiple sclerosis (MS),,,Yes,Adult,"Female , Male"
3421,2016-004362-26,I3Y-MC-JPCF,Interventional studies with investigational medicinal products,Eli Lilly and Company,"A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, Early-Stage, Hormone Receptor-Positive, Human Epidermal Receptor 2-Negative, Breast Cancer",Active,,20/07/2018,06/07/2018,A study to compare treatment after surgery of abemaciclib combined with standard endocrine therapy versus endocrine therapy alone in patients with early stage breast cancer ,No,"Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer",,Yes,,"Adult , Elderly","Female , Male"
3441,2017-000679-10,CAIN457K2340,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis",Ended,,02/03/2018,27/07/2018,Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar),No,Ankylosing spondylitis,,Yes,,"Adult , Elderly","Female , Male"
3461,2017-003101-17,1293-0013,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ",An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10,Active,,06/03/2018,19/02/2018,An exploratory maintenance trial of BI 655064 in patients with lupus nephritis,No,lupus nephritis,Yes,,,Adult,"Female , Male"
3481,2016-004340-11,17403,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy ",Ended,,20/04/2018,02/04/2018,Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells ,No,"mRNA FGF receptor 1 and 3 positive locally advanced or metastatic
urothelial carcinoma progressed after prior platinum-containing
chemotherapy",Yes,Yes,,"Adult , Elderly","Female , Male"
3501,2016-005189-75,BO39633,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY",Active,,05/04/2018,12/03/2018,An Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech¿ and/or F. Hoffmann-La Roche Ltd¿Sponsored Atezolizumab Study,No,"Cancer
(Future parent protocols may include other cancer that are not included in this section)",,Yes,,"Adult , Elderly","Female , Male"
3521,2016-002681-31,BAY1213790/17664,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing elective primary total knee arthroplasty, open-label to treatment and observer-blinded to BAY 1213790 doses ",Ended,,23/05/2018,12/03/2018,A study to investigate BAY 1213790 of different doses to prevent blood clot in patients having elective total knee replacement surgery,No,Prevention of venous thromboembolism,Yes,,,"Adult , Elderly","Female , Male"
3561,2017-003788-36,NN7088-4410,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A,Ended,,27/03/2018,14/05/2018,A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia A,No,Haemophilia A,,Yes,,"Under 18 , Adult , Elderly",Male
3581,2017-004072-59,1245-0167,Interventional studies with investigational medicinal products,Unilfarma - União Internacional Laboratórios Farmacêuticos Lda.,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with preserved Ejection Fraction (HFpEF) (EMPERIAL ¿ preserved)",,,20/04/2018,23/04/2018,This study tests empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF). The study looks at how far patients can walk in 6 minutes and at their heart failure symptoms,No,Chronic Heart Failure with preserved Ejection Fraction (HFpEF),,Yes,,Adult,"Female , Male"
3621,2017-004073-14,1245-0168,Interventional studies with investigational medicinal products,Unilfarma - União Internacional Laboratórios Farmacêuticos Lda.,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)",,,20/04/2018,23/04/2018,This study tests empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF). The study looks at how far patients can walk in 6 minutes and at their heart failure symptoms,No,Chronic Heart Failure with reduced Ejection Fraction (HFrEF),,Yes,,"Adult , Elderly","Female , Male"
3641,2017-001225-41,M14-430,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
",Ended,,16/02/2018,14/05/2018,A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433,No,Crohn's Disease (CD),,Yes,,"Adult , Elderly","Female , Male"
3721,2017-003450-16,WA40169,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS,Active,,15/06/2018,12/03/2018,A Study of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps,No,Chronic rhinosinusitis with nasal polyps,,Yes,,"Adult , Elderly","Female , Male"
3761,2016-002676-27,MEDOPP096-MO39229,Interventional studies with investigational medicinal products,MedSIR (Medica Scientia Innovation Research),Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study,Ended,,15/06/2018,17/09/2018,Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study,No,HER2-positive breast cancer,Yes,,,"Adult , Elderly","Female , Male"
3801,2017-001226-18,M14-431,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
",Ended,,28/02/2018,14/05/2018,A study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy,No,Crohn's Disease (CD),,Yes,,"Adult , Elderly","Female , Male"
3821,2017-001240-35,M14-433,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies ",Ended,,28/02/2018,14/05/2018,A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies ,No,Crohn's Disease (CD),,Yes,,"Adult , Elderly","Female , Male"
3861,2016-000281-39,CEMA401A2202,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE)",,,23/05/2018,09/07/2018,Safety and efficacy of EMA401 in patients with painful diabetic neuropathy (PDN),No,Painful Diabetic Neuropathy,Yes,,,"Adult , Elderly","Female , Male"
3961,2017-002361-22,D5336C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)",Ended,,04/06/2018,30/07/2019,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients (VIOLETTE Study)",No,Triple negative Breast Cancer,Yes,,,"Adult , Elderly","Female , Male"
3981,2017-003723-29,JBT101-CF-002,Interventional studies with investigational medicinal products,"Corbus Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis",Not Commenced,,28/05/2018,19/11/2018,A study of safety and efficacy of lenabasum in Cystic Fibrosis,No,Cystic Fibrosis (CF),Yes,,,"Under 18 , Adult","Female , Male"
4001,2017-004293-33,RPC01-3202,Interventional studies with investigational medicinal products,Celgene International II Sàrl,"Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn¿s Disease",Not Commenced,,30/05/2018,19/12/2018,Multicenter Study of Oral Ozanimod as Induction Therapy in patients with Moderately to Severely Active Crohn¿s Disease,No,Moderately to Severely Active Crohn¿s Disease,,Yes,,"Adult , Elderly","Female , Male"
4021,2017-001365-24,WN39658,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER¿S DISEASE
",Active,,06/06/2018,02/11/2018,A Study to Evaluate Efficacy and Safety of Gantenerumab in Patients with Early Alzheimer¿s Disease,No,Alzheimer¿s Disease (AD),,Yes,,"Adult , Elderly","Female , Male"
4061,2017-003336-37,HBA_001,Interventional studies with investigational medicinal products,"SGHL - SOCIEDADE GESTORA DO HOSPITAL DE LOURES, S.A. - HOSPITAL BEATRIZ ÂNGELO",CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors,Active,,19/06/2018,25/06/2018,"Phase II multi-institutional clinical trial of Nivolumab for patients with germ cell tumors who never respond or stopped responding to chemotherapy with platinum drug
",No,Metastatic germ cell tumors,Yes,,,"Adult , Elderly","Female , Male"
4101,2017-004011-39,CACZ885T2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)  ",Ended,,21/06/2018,16/07/2018,Study of efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected non-small cell lung cancer,No,stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC),,Yes,,"Adult , Elderly","Female , Male"
4121,2017-002932-18,42756493-BLC3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations,Active,,28/06/2018,23/11/2018,A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer,No,Advanced Urothelial Cancer ,,Yes,,"Adult , Elderly","Female , Male"
4201,2018-000298-65,BAY1021189/19334,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)",Ended,,28/06/2018,04/06/2018,A global study to compare the efficacy and safety of two different doses of vericiguat with placebo to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF),No,Heart failure and preserved ejection fraction,Yes,,,"Adult , Elderly","Female , Male"
4221,2016-004677-40,M16-067,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
",Ended,,03/07/2018,06/08/2018,"A Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
",No,Ulcerative Colitis,Yes,Yes,,"Under 18 , Adult","Female , Male"
4241,2016-004676-22,M16-066,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis ",Active,,03/07/2018,06/08/2018,A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis ,No,Ulcerative Colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
4261,2017-002632-17,MS700568_0021,Interventional studies with investigational medicinal products,Merck KGaA,A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®,Not Commenced,,22/05/2018,16/07/2018,A Quality of Life Study for People with Relapsing Multiple Sclerosis,No,Relapsing multiple sclerosis,,,Yes,Adult,"Female , Male"
4301,2017-004742-23,CRTH258B2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)",Ended,,27/07/2018,02/08/2018,Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema,No,diabetic macular edema,,Yes,,"Adult , Elderly","Female , Male"
4341,2017-003823-31,AG348-C-006,Interventional studies with investigational medicinal products,"Agios Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency",Not Commenced,,20/07/2018,25/02/2019,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency",No,Pyruvate Kinase Deficiency,,Yes,,Adult,"Female , Male"
4361,2017-000996-98,CSL112_3001,Interventional studies with investigational medicinal products,"CSL Behring, LLC","A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome",Active,,06/06/2018,09/11/2018,Study to Investigate CSL112 in Subjects with Acute Coronary Syndrome,No,Acute Coronary Syndrome,,Yes,,"Adult , Elderly","Female , Male"
4381,2017-003344-21,7465-CL-0301,Interventional studies with investigational medicinal products,"Astellas Pharma Global Development, Inc. (APGD)","An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",Ended,,12/09/2018,13/11/2018,"An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",No,Locally advanced or metastatic urothelial cancer,,Yes,,"Adult , Elderly","Female , Male"
4401,2017-004331-37,BO40336,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ¿ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER",Active,,17/05/2018,27/09/2018,A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage IB (tumors ¿4 cm)  to Stage IIIA Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer,No,"Completely resected, Stage IB (tumors ¿4 cm)  to Stage IIIA, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC).",,Yes,,"Adult , Elderly","Female , Male"
4421,2017-002530-23,MYK-461-005,Interventional studies with investigational medicinal products,"MyoKardia, Inc.","A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy",Ended,,28/08/2018,10/10/2018,A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscle,No,Hypertrophic Cardiomyopathy,,Yes,,"Adult , Elderly","Female , Male"
4441,2017-004294-14,RPC01-3203,Interventional studies with investigational medicinal products,Celgene International II Sàrl,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn¿s Disease",Not Commenced,,12/09/2018,29/10/2018,Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn¿s Disease,No,Moderately to Severely Active Crohn¿s Disease,,Yes,,"Adult , Elderly","Female , Male"
4461,2015-004207-22,CLCZ696B2319,Interventional studies with investigational medicinal products,Novartis Pharma AG,"Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction",Active,,03/10/2018,24/09/2018,"Pharmacokinetics, pharmacodynamics, safety and efficacy study of LCZ696 in children (1 month to < 18 years) with heart failure",Yes,Pediatric heart failure  1 month to <18 years old,Yes,Yes,,Under 18,"Female , Male"
4481,2017-000576-29,SHP647-306,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn¿s Disease (CARMEN CD 306)",Active,,09/08/2018,07/09/2018,"Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn¿s Disease, compared with placebo (dummy treatment) ¿ using a randomised and blinded study design  (investigator and patients are not aware whether they receive study drug or placebo)(CARMEN CD 306).",No,Crohn¿s disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
4501,2017-000617-23,SHP647-307,Interventional studies with investigational medicinal products,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance
Therapy in Subjects With Moderate to Severe Crohn¿s Disease (CARMEN CD 307)",Active,,17/08/2018,08/10/2018,"Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Crohn¿s Disease, compared with placebo (dummy treatment) ¿ using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo.",No,Crohn's disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
4561,2017-004869-27,MK-3475-756,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2¿) Breast Cancer (KEYNOTE-756)",Active,,16/08/2018,04/02/2019,A Clinical Trial for Newly Diagnosed High Risk ER+/HER2¿ (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast Cancer,No,"High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2¿) Breast Cancer",,Yes,,"Adult , Elderly","Female , Male"
4581,2017-003510-16,EFC15156,Interventional studies with investigational medicinal products,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure",Not Commenced,,16/08/2018,02/11/2018,Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial),No,Cardiovascular diseases,,Yes,,"Adult , Elderly","Female , Male"
4641,2017-004854-41,252LH301,Interventional studies with investigational medicinal products,Biogen Idec Research Limited,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction",Not Commenced,,23/08/2018,,Study to evaluate the use of the investigational drug BIIB093 versus placebo in patients with a large hemispheric infarction.,No,Cerebral edema  following Large Hemispheric Infarction,,Yes,,"Adult , Elderly","Female , Male"
4661,2017-003190-34,ACE-536-MDS-002,Interventional studies with investigational medicinal products,Celgene Corporation,"A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions.",Active,,20/09/2018,10/12/2018,"A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.",No,Myelodysplastic syndrome (MDS),,Yes,,"Adult , Elderly","Female , Male"
4681,2017-005105-12,GR40398,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE)
",Ended,,18/09/2018,17/09/2018,A Study to Evaluate the Efficacy and Safety of faricimab in Patients with Diabetic Macular Edema (RHINE),No,Diabetic Macular Edema (DME),,Yes,,"Adult , Elderly","Female , Male"
4981,2017-004066-10,MVT-601-3103,Interventional studies with investigational medicinal products,Myovant Sciences GmbH,"SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain",Active,,14/08/2018,24/04/2019,Extension study to evaluate the efficacy and safety of relugolix in women with endometriosis-associated Pain,No,Endometriosis,,Yes,,Adult,Female
5041,2017-004208-24,CLJC242A2201J,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (TANDEM)",Ended,,26/09/2018,29/10/2018,"Study of safety, tolerability, and efficacy of a combination treatment of tropifexor and cenicriviroc in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis",No,Non-alcoholic Steatohepatitis (NASH),Yes,,,"Adult , Elderly","Female , Male"
5061,2017-002158-35,IVA_01_ODI_HMPS_17_002,Interventional studies with investigational medicinal products,INVENTIVA SA,"A phase IIa study to investigate safety, pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.",Active,,17/12/2018,12/02/2019,"Study to investigate the fate of odiparcil since its administration up to the point is completely eliminated, its safety and efficacy in patients 16 years and above with mucopolysaccharidosis (MPS) type VI ",No,Mucopolysaccharidosis (MPS) type VI.,Yes,,,"Under 18 , Adult","Female , Male"
5081,2017-002195-13,CNTO1959CRD3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease",Active,,16/10/2018,21/03/2019,A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease,No,Moderately to Severely Active Crohn's Disease,Yes,Yes,,"Adult , Elderly","Female , Male"
5121,2017-003899-31,DBC-AMD-001-D,Interventional studies with investigational medicinal products,Dobecure S.l.,"International, multicenter, randomised, double-blind, sham-controlled,  2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improvement of visual acuity of patients with dry age-related macular degeneration.",Not Commenced,,25/06/2019,19/11/2018,"International, multicenter, randomised, double-blind, sham-controlled,  2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improvement of visual acuity of patients with dry age-related macular degeneration.",No,Aged related macula degeneration (AMD),,Yes,,"Adult , Elderly","Female , Male"
5161,2017-004419-38,CL3-95008-001,Interventional studies with investigational medicinal products,"SERVIER PORTUGAL - ESPECIALIDADES FARMACÊUTICAS, LDA.","Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. 
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.",Active,,17/10/2018,19/11/2018,Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. ,Yes,Autism Spectrum Disorder (ASD),,Yes,,Under 18,"Female , Male"
5162,2017-004420-30,CL3-95008-002,Interventional studies with investigational medicinal products,"SERVIER PORTUGAL - ESPECIALIDADES FARMACÊUTICAS, LDA.","Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.",Active,,17/10/2018,19/11/2018,Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.,Yes,Autism Spectrum Disorder (ASD),,Yes,,Under 18,"Female , Male"
5181,2017-002708-28,REDIV/002/17,Interventional studies with investigational medicinal products,Alfasigma S.p.A.,"Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized clinical trial. (The ROAD trial)",,,14/11/2018,25/02/2019,Rifaximin tablets in the prevention of recurrent acute diverticulitis and diverticular complications.,No,Prevention of recurrent acute diverticulitis and diverticular complications,Yes,,,"Adult , Elderly","Female , Male"
5201,2016-002971-91,1386.12,Interventional studies with investigational medicinal products,Unilfarma - União Internacional Laboratórios Farmacêuticos Lda.,"A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema (ROBIN study)",Ended,,24/10/2018,08/10/2018,"A study that tests BI 1467335 in patients with diabetic eye
disease (diabetic retinopathy). It looks at the way BI 1467335 is
taken up, the effects it has, and how well it is tolerated.",No,diabetic retinopathy,Yes,,,"Adult , Elderly","Female , Male"
5221,2017-003309-16,JZP963-201,Interventional studies with investigational medicinal products,Jazz Pharmaceuticals Inc.,"A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant",Not Commenced,,19/11/2018,10/12/2018,A clinical study to investigate the efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the prevention of Acute Graft-versus-Host-Disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant,No,Prevention of Acute Graft-versus-Host Disease (aGvHD) after allogeneic hematopoietic stem cell transplant,Yes,,,"Under 18 , Adult , Elderly","Female , Male"
5241,2018-001272-37,0173,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn¿s Disease",Active,,10/10/2018,26/03/2019,A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Crohn's Disease,No,Moderately-to-Severely Active Crohn¿s Disease (CD),Yes,,,"Adult , Elderly","Female , Male"
5261,2018-000347-60,TTD-18-01,Interventional studies with investigational medicinal products,Grupo de Tratamiento de los Tumores Digestivos,"Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE",Active,,17/01/2019,15/05/2019,Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combination with biologic drugs (panitumumab and bevacizumab).,No,metastatic colorectal cancer,,Yes,,"Adult , Elderly","Female , Male"
5281,2017-004605-41,021IGAN17001,Interventional studies with investigational medicinal products,Travere Therapeutics Inc.,"A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy",Active,,24/10/2018,06/03/2019,Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN),No,Immunoglobulin A Nephropathy (IgAN),,Yes,,"Adult , Elderly","Female , Male"
5301,2018-002147-28,CT-P16_3.1,Interventional studies with investigational medicinal products,"Celltrion, Inc.","A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer",Active,,16/11/2018,10/12/2018,Comparing Efficacy and Safety between CT-P16 and EU-approved Avastin in Patients with Metastatic or Recurrent Non-Squamous Non Small Cell Lung Cancer,No,Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer,,Yes,,"Adult , Elderly","Female , Male"
5343,2018-002448-10,BIA-51058-201,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)",Not Commenced,,26/11/2018,19/11/2018,Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease.,No,Pulmonary arterial hypertension,Yes,,,"Adult , Elderly","Female , Male"
5361,2018-000168-27,CDRB436F2410,Interventional studies with investigational medicinal products,Novartis Pharma AG,"COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm (Plus)",Ended,,22/10/2018,17/12/2018,Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomes,No,Stage III BRAF V600 mutation-positive melanoma ,,Yes,,"Adult , Elderly","Female , Male"
5401,2018-001594-24,CABL001E2201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response",Active,,29/10/2018,10/12/2018,Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib,No,"Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response",Yes,,,"Adult , Elderly","Female , Male"
5441,2017-003131-11,1280-0022,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in women with HR+ / HER2- metastatic breast cancer and non-visceral disease",Temporary Halt,,19/11/2018,19/11/2018,The Xenera-1 study tests xentuzumab in combination with everolimus and exemestane in women with hormone receptor positive and HER2-negative breast cancer that has spread,No,HR+ / HER2- metastatic breast cancer and non-visceral disease,Yes,,,"Adult , Elderly",Female
5461,2018-002153-30,MO40628,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer",Active,,23/11/2018,28/01/2019,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with HER2-Positive Early Breast Cancer,No,Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.,Yes,,,"Adult , Elderly","Female , Male"
5501,2017-002751-28,PVO-2A-201,Interventional studies with investigational medicinal products,Clementia Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas",Active,,12/11/2018,25/02/2019,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas",No,Multiple Osteochondromas (MO),Yes,,,Under 18,"Female , Male"
5561,2018-000840-24,CQGE031C2303,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines",Not Commenced,,04/12/2018,14/01/2019,A Phase III study of efficacy and safety of ligelizumab in the treatment of Chronic Spontaneous Urticaria in adolescents and adults inadequately controlled with H1-antihistamines,Yes,Chronic Spontaneous Urticaria,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
5581,2017-003219-20,NN9535-4386,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to
metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes

A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group,
randomised trial in subjects with type 2 diabetes",Active,,05/11/2018,14/01/2019,"A research study to compare semaglutide to insulin aspart, when taken together with metformin and insulin glargine, in people with type 2 diabetes",No,"Diabetes Mellitus, Type 2",,Yes,,"Adult , Elderly","Female , Male"
5601,2016-000704-28,GCP#05.01.020,Interventional studies with investigational medicinal products,Gamida Cell Ltd.,"A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies",Not Commenced,,22/01/2019,30/09/2019,"A multicenter trial of transplantation of NiCord, stem cells from donated umbilical cord blood that were grown in a laboratory to expand their number versus unmanipulated umbilical cord blood for patients with cancers of the blood and lymph",No,High risk haematological malignancies,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
5621,2018-001967-22,MK-3475-676,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)",Active,,06/11/2018,23/01/2019,A Phase 3 trial of BCG with or without pembrolizumab for high risk non-muscle invasive bladder cancer (KEYNOTE-676),No,High-risk Non-muscle Invasive Bladder Cancer (NMIBC),,Yes,,"Adult , Elderly","Female , Male"
5641,2017-004295-55,RPC01-3204,Interventional studies with investigational medicinal products,Celgene International II Sàrl,"A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn¿s Disease",Not Commenced,,06/12/2018,21/02/2019,Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn¿s Disease,No,Moderately to Severely Active Crohn¿s Disease,,Yes,,"Adult , Elderly","Female , Male"
5661,2016-001787-10,IG1407,Interventional studies with investigational medicinal products,"INSTITUTO GRIFOLS, S.A.","Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with ""Acute-On-Chronic Liver Failure"" (ACLF) at High Risk of Hospital Mortality",Active,,08/01/2019,04/02/2019,Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality,No,"Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during
hospitalization",,Yes,,"Adult , Elderly","Female , Male"
5662,2015-004505-16,CONVINCE,Interventional studies with investigational medicinal products,University College Dublin,"CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) ¿ a randomised clinical trial of low-dose colchicine
for secondary prevention after stroke",Not Commenced,,08/04/2019,,The Use of Colchicine (an anti-inflammatory drug) in  Prevention of  Recurrent Stroke or heart attack after first Stroke; a randomised controlled trial,No,"The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not
caused by cardiac embolism or other causes unrelated to atherosclerosis.",,Yes,,"Adult , Elderly","Female , Male"
5681,2017-000690-36,TED14856,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal Women with Estrogen Receptor-positive Advanced Breast Cancer
",Not Commenced,,23/11/2018,04/02/2019,"Phase 1 / 2 of SAR439859 single agent or in combination with palbociclib in postmenopausal women estrogen receptor positive advanced breast cancer
",No,"Cancer
",Yes,,,"Adult , Elderly",Female
5701,2018-001383-28,M18-891,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis",Ended,,07/09/2018,14/02/2019,Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) ¿ Measure Up 2,No,Moderate and Severe Atopic Dermatitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
5722,2014-001363-12,TRIANGLE,Interventional studies with investigational medicinal products,Klinikum der Universität München,Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma ¿ a randomized European MCL Network trial,Active,,12/11/2018,16/05/2019,Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma ¿ a randomized European MCL Network trial,No,Generalized mantle cell Lymphoma,,Yes,,Adult,"Female , Male"
5723,2017-004825-34,KHB-1801,Interventional studies with investigational medicinal products,"Chengdu Kanghong Biotechnology Co., Ltd.","A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration",Ended,,22/01/2019,13/02/2019,"A multicenter, double-blinded, randomized, different doses study to evaluate the efficacy and safety of Conbercept injection in patients with Neovascular Age related Macular Degeneration",No,Neovascular Age Related Macular Degeneration,,Yes,,"Adult , Elderly","Female , Male"
5841,2018-001303-36,TRCA-303,Interventional studies with investigational medicinal products,Tricida Inc.,"A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis",Active,,27/12/2018,18/03/2019,"A clinical study with patients who have increased acid in their blood because of chronic kidney disease that is testing if the experimental drug TRC101, compared to placebo (a substance that does not contain medicine), is safe and if it slows down worsening of kidney disease.
",No,Chronic kidney disease,,Yes,,"Adult , Elderly","Female , Male"
5861,2014-002277-11,20120123,Interventional studies with investigational medicinal products,Amgen Inc.,"Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Cholesterol (LDL-C) Reduction, as Add-On to Diet and Lipid-Lowering Therapy, in Pediatric Subjects 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH)",Not Commenced,,15/10/2018,25/02/2019,Study to assess the long term safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia,Yes,Heterozygous familial hypercholesterolemia,,Yes,,Under 18,"Female , Male"
5921,2016-000642-62,M14-675,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis ",Ended,,17/10/2018,23/09/2019,"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in subjects with Moderately to Severely Active Ulcerative Colitis 
",No,Ulcerative Colitis,,Yes,,"Adult , Elderly","Female , Male"
5941,2017-004703-51,COMB157G2399,Interventional studies with investigational medicinal products,Novartis Pharma AG,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis
",Ended,,06/11/2018,23/04/2019,"Long-term safety, tolerability and effectiveness study of ofatumumab in subjects with relapsing multiple sclerosis
",No,Multiple sclerosis,,Yes,,Adult,"Female , Male"
5961,2018-002796-18,BIA-51058-202,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease",Not Commenced,,30/07/2019,14/01/2019,"To study the safety and effectiveness of the maximum tolerated dose of zamicastat, found in BIA-51058-201, in the treatment of long-term PAH. ",No,Pulmonary arterial hypertension,Yes,,,"Adult , Elderly","Female , Male"
6001,2018-003163-67,CAEB1102-102A,Interventional studies with investigational medicinal products,"Aeglea Biotherapeutics, Inc.","An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency",Active,,21/12/2018,18/03/2019,"An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency",Yes,"Arginase 1 deficiency
Hyperargininemia",Yes,,,"Under 18 , Adult","Female , Male"
6021,2018-002442-37,ACT15320,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma",Not Commenced,,13/02/2019,01/04/2019,A Study of Isatuximab-based Therapy in Participants with Lymphoma,No,Lymphoma,Yes,,,"Under 18 , Adult , Elderly","Female , Male"
6061,2018-000519-26,8951-CL-0302,Interventional studies with investigational medicinal products,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",Active,,07/03/2019,18/03/2019,"A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",No,"Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or
Gastroesophageal Junction (GEJ) Adenocarcinoma",,Yes,,"Adult , Elderly","Female , Male"
6081,2017-003200-48,EP0091,Interventional studies with investigational medicinal products,UCB Biopharma SRL,"A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Resistant Epilepsy
",Not Commenced,,21/12/2018,07/06/2019,"Study to test the efficacy and safety of Padsevonil as adjunctive treatment of focal-onset seizures in adults with drug-resistant epilepsy
",No,"Focal-Onset Seizures
",Yes,,,"Adult , Elderly","Female , Male"
6141,2015-002276-25,20120124,Interventional studies with investigational medicinal products,Amgen Inc.,"Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)",Not Commenced,,11/12/2018,11/09/2019,Study to assess the safety and efficacy of evolocumab in children aged 10 to 17 years with Heterozygous Familial Hypercholesterolemia or Homozygous Familial Hypercholesterolemia ,Yes,Hypercholesterolemia,,Yes,,Under 18,"Female , Male"
6182,2017-002465-22,M16-011,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
",Ended,,15/11/2018,06/03/2019,A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD)Therapy (KEEPsAKE 1),No,Psoriatic Arthritis.,,Yes,,"Adult , Elderly","Female , Male"
6201,2017-002464-40,M15-998,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2)
",Ended,,16/11/2018,06/03/2019,"A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies)
",No,Psoriatic arthritis,,Yes,,"Adult , Elderly","Female , Male"
6202,2018-002484-25,TAK-935-2002(OV935),Interventional studies with investigational medicinal products,Ovid Therapeutics Inc.,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEVELOPMENTAL AND/OR EPILEPTIC ENCEPHALOPATHIES",Active,,08/02/2019,26/06/2019,"A phase 2, multicenter, randomized,  double-blind, controlled with placebo,  to obtaine efficacy , safety and tolerability  information for TAK-935 as an adjuntive therapy in  pediatric patinets ((aged ¿2 and ¿17 years) with  developmental and/or epileptic encephlopathies (Dravet syndrome and Lennox Gastaut)",No,Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS),Yes,,,Under 18,"Female , Male"
6241,2018-002141-11,Vedolizumab-3035,Interventional studies with investigational medicinal products,"Millennium Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",Active,,17/12/2018,12/03/2019,"A clinical trial of Vedolizumab vs. placebo (dummy drug) for the prevention of intestinal Acute Graft Versus Host Disease (aGvHD), in patients undergoing allo-HSCT for a hematologic malignancy, (cancers that affect the blood and/or lymphatic system). ",Yes,Intestinal acute graft-versus-host disease (aGvHD) ,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
6301,2018-002063-26,CAIN457M2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa",Active,,17/01/2019,18/03/2019,"A clinical trial to evaluate treatment with a drug called secukinumab in
adult patients who are diagnosed with moderate to severe hidradenitis
suppurativa (long term skin disease characterized by the occurrence of
inflamed and swollen lumps)",No,hidradenitis suppurativa,,Yes,,"Adult , Elderly","Female , Male"
6321,2018-003519-24,ALN-TTR02-008,Interventional studies with investigational medicinal products,"Alnylam Pharmaceuticals, Inc.","An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant ",Not Commenced,,03/01/2019,20/03/2019,Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver Transplant  ,No,Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) ,,Yes,,"Adult , Elderly","Female , Male"
6361,2017-003040-20,MX39795,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapy",Active,,07/02/2019,01/04/2019,"A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have recieved three cycles of platinum doublet chemotherapy",No,Cancer of Unknown Primary Site,Yes,,,"Adult , Elderly","Female , Male"
6381,2018-002098-23,ALN-TTRSC02-002,Interventional studies with investigational medicinal products,"Alnylam Pharmaceuticals, Inc.","HELIOS-A:  A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) ",Active,,22/01/2019,18/03/2019,"HELIOS-A:  A Clinical Study to Assess the Effectiveness and Safety of an Investigational Drug, ALN-TTRSC02, in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",No,Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis),,Yes,,"Adult , Elderly","Female , Male"
6401,2017-003380-35,EX9536-4388,Interventional studies with investigational medicinal products,Novo Nordisk A/S,SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity,Active,,13/12/2018,03/05/2019,SELECT - Semaglutide effects on heart disease and stroke in patients with overweight or obesity,No,"Overweight
Obesity",,Yes,,"Adult , Elderly","Female , Male"
6441,2018-001974-76,MK-3475-630,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)",Active,,11/02/2019,30/05/2019,Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC ,No,Resectable high-risk locally advanced cutaneous squamous cell carcinoma  (LA cSCC),,Yes,,"Adult , Elderly","Female , Male"
6461,2018-002136-24,0157,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473 in Subjects with Moderately-to-Severely Active Ulcerative Colitis",Active,,07/03/2019,22/05/2019,A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis,No,Moderately-to-Severely Active Ulcerative Colitis,Yes,Yes,,"Adult , Elderly","Female , Male"
6481,2017-003302-40,WO40242,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK",Active,,21/02/2019,29/03/2019,A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy after Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck,No,Locally advanced squamous cell carcinoma of the head and neck (SCCHN),,Yes,,"Adult , Elderly","Female , Male"
6541,2018-003214-41,CNTO1959PSA3003,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF¿) Therapy",Ended,,12/04/2019,10/05/2019,A phase 3 study of Guselkumab in Subjects with Active Psoriatic Arthritis ,No,Psoriatic Arthritis,,Yes,,"Adult , Elderly","Female , Male"
6581,2016-004198-41,UCDCRC/16/003,Interventional studies with investigational medicinal products,University College Dublin,PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL),Not Commenced,,08/03/2019,18/03/2019,To investigate the use of surfactant in preterm babies as a preventative measure against intubation in the windpipe.,No,Preterm Infants at risk of respiratory distress syndrome,,Yes,,Under 18,"Female , Male"
6621,2017-003295-31,C3441021,Interventional studies with investigational medicinal products,PFIZER INC,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer ",Ended,,09/05/2019,26/09/2019,Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer,No,Metastatic Castration-resistant Prostate Cancer ,,Yes,,Adult,Male
6641,2018-000844-25,R668-EE-1774,Interventional studies with investigational medicinal products,"Regeneron Pharmaceuticals, Inc","A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE)",Not Commenced,,19/02/2019,12/08/2019,A study to determine the efficacy and safety of dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE),No,Eosinophilic Esophagitis (EoE),,Yes,,"Under 18 , Adult","Female , Male"
6681,2018-003069-33,DS8201-A-U303,Interventional studies with investigational medicinal products,"Daiichi Sankyo, Inc.","A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician¿s choice for HER2-Low, unresectable and/or metastatic breast cancer subjects (DESTINY-Breast04)",Active,,21/06/2019,29/07/2019,"Testing a new targeted therapy (trastuzumab deruxtecan, DS-8201a) against other targeted chemotherapy (selected by your doctor) for patients with advanced-stage breast cancer.",No,Unresectable and/or metastatic breast cancer that is human epidermal growth factor receptor 2 (HER2)-low,,Yes,,"Adult , Elderly","Female , Male"
6741,2017-003737-29,BUU-5/EEA,Interventional studies with investigational medicinal products,Dr. Falk Pharma GmbH                                                                                ,"Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic esophagitis",Active,,05/04/2019,24/05/2019,"Double-blind (neither physician nor patient knows of the actual treatment which can be with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), placebo-controlled (one of the treatment groups receives medication without active substance), phase II/III study on the efficacy and tolerability of oral budesonide suspension in comparison with placebo in children and adolescents with eosinophilic esophagitis ",No,Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis,Yes,Yes,,Under 18,"Female , Male"
6761,2018-001547-32,CACZ885U2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)",Ended,,30/04/2019,30/05/2019,Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects,No,"stages AJCC v. 8 IIIB/IIIC (not eligible for definite chemoradiation
therapy) or stage IV (metastatic) non-small cell lung cancer (NSCLC)",,Yes,,"Adult , Elderly","Female , Male"
6841,2018-001393-16,OHB-607-202,Interventional studies with investigational medicinal products,Oak Hill Bio,"A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 in Preventing Chronic
Lung Disease in Extremely Premature Infants Compared to Standard Neonatal Care",Temporary Halt,,06/05/2019,26/09/2019,A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babies,Yes,Chronic Lung Disease,Yes,,,Under 18,"Female , Male"
6861,2018-002496-18,VX18-121-101,Interventional studies with investigational medicinal products,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis",Not Commenced,,24/04/2019,11/07/2019,A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis,No,Cystic Fibrosis,Yes,,,Adult,"Female , Male"
6881,2018-004059-18,17909,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure: AVANTI Study",Ended,,24/04/2019,04/06/2019,BAY 1753011 in Congestive Heart Failure,No,Heart failure,Yes,,,"Adult , Elderly","Female , Male"
6901,2017-003241-26,EP0093,Interventional studies with investigational medicinal products,UCB Biopharma SRL,"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy
",Not Commenced,,08/04/2019,16/10/2019,"Study to test the safety and efficacy of Padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy
",No,"Focal-Onset Seizures
",Yes,Yes,,"Adult , Elderly","Female , Male"
6921,2018-004042-42,GR40844,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (LUCERNE)
",Active,,14/03/2019,18/03/2019,A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (Lucerne),No,Neovascular age-related macular degeneration,,Yes,,"Adult , Elderly","Female , Male"
6961,2018-003636-79,18-214-10/CA045-012,Interventional studies with investigational medicinal products,Nektar Therapeutics,"A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients",Ended,,11/06/2019,11/09/2019,A study in patients with bladder cancer using a combination of nivolumab and NKTR-214 with chemotherapy.,No,Locally advanced or metastatic urothelial bladder cancer,Yes,,,"Adult , Elderly","Female , Male"
6981,2018-002880-25,LTE15174,Interventional studies with investigational medicinal products,Genzyme Corporation,"ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX",Not Commenced,,03/07/2019,29/04/2019,"Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX",No,Hemophilia A or Hemophilia B,,Yes,,"Under 18 , Adult , Elderly",Male
7001,2018-002823-41,AC-065B302,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical and/or interventional treatment Chronic Thromboembolic Pulmonary Hypertension.",Ended,,18/06/2019,27/06/2019,"A clinical study to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent, after surgical treatment and/or Chronic Thromboembolic Pulmonary Hypertension (CTEPH).",No,"Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrent",,Yes,,"Adult , Elderly","Female , Male"
7021,2018-003076-13,UIC1212,Interventional studies with investigational medicinal products,"Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE",Effect of topical mesalazine on the formation of adenomas in rectal stumps or ileal pouches of familial adenomatous polyposis or MUTYH associated polyposis patients after colectomy,Not Commenced,,05/08/2019,16/10/2019,Rectal mesalazine for FAP and MAP,No,Familial adenomatous polyposis(FAP) and MUTYH-associated polyposis (MAP),,Yes,,Adult,"Female , Male"
7041,2018-002135-19,0164,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC)",Active,,06/06/2019,05/08/2019,A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Ulcerative Colitis (UC),No,Moderately-to-severely active Ulcerative Colitis (UC),,Yes,,"Adult , Elderly","Female , Male"
7061,2018-002932-26,D9108C00002,Interventional studies with investigational medicinal products,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC	","A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)",Active,,24/06/2019,03/10/2019,Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Resectable Non-Small Cell Lung Cancer,No,Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer,Yes,,,"Adult , Elderly","Female , Male"
,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,
7121,2018-001187-33,ROR-PH-301(APD811-301),Interventional studies with investigational medicinal products,United Therapeutics Corporation,A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients,Active,,22/04/2019,02/12/2019,"A study evaluating the efficacy and safety of ralinepag  in treatment of patients with pulmonary hypertension.
",No,pulmonary arterial hypertension (PAH),,Yes,,"Adult , Elderly","Female , Male"
7122,2018-002931-35,D9108C00001,Interventional studies with investigational medicinal products,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC	","A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)",Active,,24/06/2019,27/09/2019,A study of durvalumab alone or in combination with other agents in subjects with non-small cell lung cancer that is not removable by surgery,No,Stage III non-small cell lung cancer,Yes,,,"Adult , Elderly","Female , Male"
7141,2018-001189-40,ROR-PH-303(APD811-303),Interventional studies with investigational medicinal products,United Therapeutics Corporation,A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-label Extension (ADVANCE-Extension),Active,,03/04/2019,02/12/2019,An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertension,No,Pulmonary arterial hypertension (PAH),,Yes,,"Adult , Elderly","Female , Male"
7161,2017-004135-36,WTX101-301,Interventional studies with investigational medicinal products,"Alexion Pharmaceuticals, Inc.","A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate The Efficacy And Safety Of ALXN1840 Administered For 48 Weeks Versus Standard Of Care In Patients With Wilson Disease Aged 12 Years And Older With An Extension Period Of Up To 60 Months",Not Commenced,,25/07/2019,13/01/2020,A Phase 3 clinical study to Evaluate the Efficacy and Safety of ALXN1840 in adult and adolescent patients who suffer from Wilson Disease.,No,Wilson Disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
7181,2018-001228-20,CAMG334A2401,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients",Active,,25/06/2019,20/05/2019,"A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms in adult episodic migraine patients",No,Migraine prevention,,,Yes,Adult,"Female , Male"
7201,2018-003008-38,105MS306,Interventional studies with investigational medicinal products,Biogen Idec Research Limited,"An Open-Label, Randomized, Multicenter, Active-Controlled,
Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in
Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting
Multiple Sclerosis, With Optional Open-Label Extension",Active,,16/07/2019,01/10/2019,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",Yes,Relapsing Remitting Multiple Sclerosis (RRMS) ,,Yes,,Under 18,"Female , Male"
7221,2018-004280-32,AG10-301,Interventional studies with investigational medicinal products,"Eidos Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)",Not Commenced,,25/07/2019,23/09/2019,Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM),No,Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM),,Yes,,"Adult , Elderly","Female , Male"
7241,2017-004059-22,CL3-95005-006,Interventional studies with investigational medicinal products,"SERVIER PORTUGAL - ESPECIALIDADES FARMACÊUTICAS, LDA.","An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)",Ended,,10/07/2019,13/09/2019,Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy,No,Metastatic colorectal cancer,,Yes,,"Adult , Elderly","Female , Male"
7261,2018-004785-33,CMO-MA-EYE-0603,Interventional studies with investigational medicinal products,Allergan Pharmaceuticals International Limited,"A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (according to standard clinical practice)  with Diabetic Macular Edema",Not Commenced,,28/06/2019,08/07/2019,Study to Evaluate the Efficacy and Safety of OZURDEX® in Treatment Naïve Patients with Diabetic Macular Edema,No,Diabetic Macular Edema,,,Yes,"Adult , Elderly","Female , Male"
7281,2018-004237-32,70033093THR2001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery.",Active,,02/09/2019,02/09/2019,Randomized Study to Evaluate the Safety and Efficacy of Oral JNJ-70033093 Versus Enoxaparin in Subjects Undergoing Elective Total Knee Replacement,No,Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement,Yes,,,"Adult , Elderly","Female , Male"
7321,2016-001514-20,CA209648,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma",Not Commenced,,13/08/2019,02/09/2019,A Study to Evaluate Efficacy in Subjects with Esophageal Cancer Treated with Nivolumab and Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin,No,"Inoperable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).",,Yes,,"Adult , Elderly","Female , Male"
7361,2016-005141-23,021FSGS16010,Interventional studies with investigational medicinal products,Travere Therapeutics Inc.,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)",Ended,,11/06/2019,08/10/2019,Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS),No,Focal segmental glomerulosclerosis (FSGS),,Yes,,"Under 18 , Adult , Elderly","Female , Male"
7381,2018-001511-73,WA40404,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS",Active,,08/07/2019,02/03/2020,A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis,No,Primary progressive multiple sclerosis (PPMS),,Yes,,Adult,"Female , Male"
7401,2018-004234-15,CLEE011A2207,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.",Active,,12/06/2019,17/06/2019,"Study of the safety and efficacy of ribociclib 400mg in combination with endocrine therapy for the treatment of pre- and postmenopausal women with HR+, HER2- advanced breast cancer who received no previous therapy for advanced disease. ",No,"HR-positive, HER2-negative  advanced breast cancer ",Yes,,,"Adult , Elderly",Female
7421,2014-002048-42,MO29406,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La Roche sponsored pertuzumab study,Active,,27/06/2019,17/06/2019,An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La Roche sponsored pertuzumab study,No,"Solid Malignant Tumors
",,Yes,,"Adult , Elderly","Female , Male"
7461,2017-003619-20,NN9535-4352,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes,Active,,27/05/2019,06/08/2019,A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes,No,"Diabetes Mellitus, Type 2",,Yes,,"Adult , Elderly","Female , Male"
7481,2018-002611-99,20090,Interventional studies with investigational medicinal products,   Bayer A.G.                                                                                       ,"Open-label, randomized, two¿arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (ROP)",Active,,24/07/2019,14/08/2020,Aflibercept for retinopathy of prematurity ¿ intravitreal injection versus laser therapy,Yes,Retinopathy of prematurity ,,Yes,,Under 18,"Female , Male"
7501,2018-003556-20,1806-LIS-044-SD,Interventional studies with investigational medicinal products,"INSTITUTO VALENCIANO DE INFERTILIDADE - CLÍNICA DE REPRODUÇÃO ASSISTIDA, LDA.,",How do different ovarian stimulation protocols affect endometrial receptivity during a fresh  in vitro fertilization attempt?,Active,,03/06/2019,19/06/2019,How do different ovarian stimulation protocols affect endometrial receptivity during a fresh  in vitro fertilization attempt?,No,Women with a clinical indication to undergo Assisted Reproductive Technologies for infertility with a predicted normal response to Ovarian Stimulation and planned for a single blastocyst transfer,,,Yes,Adult,Female
7541,2018-004039-64,MYK-461-007,Interventional studies with investigational medicinal products,"MyoKardia, Inc.",A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE),Active,,18/07/2019,09/08/2019,A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE),No,Hypertrophic Cardiomyopathy,,Yes,,"Adult , Elderly","Female , Male"
7561,2019-000069-19,MS700568_0026,Interventional studies with investigational medicinal products,Merck KGaA,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,Active,,06/06/2019,16/10/2019,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials,No,Multiple Sclerosis,,,Yes,"Adult , Elderly","Female , Male"
7581,2013-000717-20,SP0967,Interventional studies with investigational medicinal products,"UCB Biosciences, Inc.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY ¿1 MONTH TO <4 YEARS OF AGE WITH PARTIAL-ONSET SEIZURES",Not Commenced,,11/06/2019,23/09/2019,EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ¿1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURES,No,Epilepsy with partial onset seizures,,Yes,,Under 18,"Female , Male"
7601,2012-005012-26,EP0034,Interventional studies with investigational medicinal products,"UCB Biosciences, Inc.","A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL ONSET SEIZURES",Not Commenced,,17/07/2019,23/09/2019,A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON  THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES,No,Epilepsy with Partial Onset Seizures,,Yes,,Under 18,"Female , Male"
7621,2018-004558-30,BIOP-US,Interventional studies with investigational medicinal products,Fundacion instituto de la investigación sanitaria de la fundación Jimenez diaz,"A 3-arm, randomized, open-label, parallel active controlled, multicenter international study to compare the response of ultrasound-assessed synovitis to baricitinib, alone and combined with methotrexate versus etanercept in rheumatoid arthritis patients with inadequate response to methotrexate. Searching for synovium predictors of response.",Not Commenced,,17/09/2019,16/03/2020,"A 3-arm, randomized, open-label, parallel active controlled, multicenter international study to compare the response of ultrasound-assessed synovitis to baricitinib, alone and combined with methotrexate versus etanercept in rheumatoid arthritis patients with inadequate response to methotrexate. Searching for synovium predictors of response.",No,rheumatoid arthritis,,,Yes,"Adult , Elderly","Female , Male"
7641,2018-004476-35,CCFZ533B2201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of patients with Sjögren¿s Syndrome (TWINSS)",Active,,19/08/2019,06/08/2019,Study of safety and efficacy of multiple doses of CFZ533 in two distinct populations of patients with Sjögren¿s Syndrome,No,Sjögren syndrome,Yes,,,"Adult , Elderly","Female , Male"
7645,2017-001976-48,IM011023,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease",Active,,12/07/2019,02/01/2020,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease",No,Crohn's Disease,Yes,,,"Adult , Elderly","Female , Male"
7661,2018-001423-40,CA045-001,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma",Active,,16/08/2019,02/09/2019,A Study of NKTR-214 Combined With Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,No,Untreated unresectable or metastatic melanoma,,Yes,,"Adult , Elderly","Female , Male"
7681,2016-002272-27,DSHNHL2015-1,Interventional studies with investigational medicinal products,Universität des Saarlandes,"Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma",Active,,18/11/2019,16/10/2019,Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to a standard chemotherapy. ,No,Patients in first relapse or progression of aggressive Non-Hodgkin¿s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation.,,Yes,,"Adult , Elderly","Female , Male"
7701,2019-000716-28,CRTH258A2303,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON)",Active,,08/08/2019,02/09/2019,"Study to evaluate the safety, efficacy, and the period between treatments of brolucizumab 6 mg compared with aflibercept 2 mg in neovascular Age-Related Macular Degeneration (nAMD), also commonly referred to as wet AMD",No,neovascular age-related macular degeneration,,Yes,,"Adult , Elderly","Female , Male"
7781,2018-004154-25,CLCZ696B2319E1,Interventional studies with investigational medicinal products,Novartis Pharma AG,A multicenter study to evaluate long-term safety and tolerability of open label  sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 (PANORAMA-HF),Active,,14/08/2019,23/08/2019,"CLCZ696B2319E1 open-label extension (OLE) study to evaluate long-term safety and tolerability of sacubitril/valsartan in pediatric patients with heart failure

",No,"Pediatric heart failure : Patients (¿ 13 months) with HF due to systemic left ventricular systolic dysfunction. 

[Note: All patients per protocol  for  the core study CLCZ696B2319 (PANORAMA-HF) are to be <18 yrs at screening (enrollment). Patients will be 1 yr older when they are potentially eligible for entry in the OLE Study CLCZ696B2319E1].  
Subjects who turned 18 yrs old during the PANORAMA-HF study, and who qualify, are eligible to participate in the OLE study.  Ref section F.1.2
 ",,Yes,,"Under 18 , Adult","Female , Male"
7821,2017-003364-12,64091742PCR3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer",Ended,,30/09/2019,25/11/2019,A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Patients with Metastatic Prostate Cancer,No,Metastatic Prostate Cancer,,Yes,,"Adult , Elderly",Male
7921,2018-003385-14,AROAAT2001,Interventional studies with investigational medicinal products,"Arrowhead Pharmaceuticals, Inc.","A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)  in Patients with Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA] ",Not Commenced,,04/10/2019,04/11/2019,A clinical trial to assess the safety and effects of a novel medicine intended for the treatment of patients with liver disease due to Alpha-1 Antitrypsin Deficiency (AATD),No,alpha-1 antitrypsin deficiency (AATD)-associated liver disease,Yes,,,"Adult , Elderly","Female , Male"
7941,2018-002617-35,BUL-5/ESD,Interventional studies with investigational medicinal products,Dr. Falk Pharma GmbH                                                                                ,"Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection",Active,,09/09/2019,23/09/2019,"Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the efficacy and tolerability of an 8 week treatment with two different doses of budesonide tablets dissolving in the mouth compared to placebo (medication without active substance), for prevention of constrictions of the oesophagus in adult patients after removal of cancer tissue using an endoscopic surgery technique 
",No,Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection,Yes,,,"Adult , Elderly","Female , Male"
7982,2018-004608-21,20170724,Interventional studies with investigational medicinal products,Amgen Inc.,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ¿ 2 to < 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis.",Active,,04/07/2019,24/01/2020,A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis,Yes,Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis,,Yes,,Under 18,"Female , Male"
8021,2017-004692-31,CA017-078,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer",Active,,09/12/2019,20/07/2020,"A study of Chemo only versus Chemo plus Nivo with or without BMS-986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS-986205 in Patients with MIBC",No,"Bladder Cancer
Muscle-Invasive Bladder Cancer",,Yes,,"Adult , Elderly","Female , Male"
8041,2018-003985-15,APD334-301,Interventional studies with investigational medicinal products,"Arena Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",Active,,12/07/2019,12/02/2020,A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitis,No,Ulcerative Colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
8081,2019-000328-16,20170588,Interventional studies with investigational medicinal products,Amgen Inc.,A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy,Active,,13/08/2019,05/05/2020,A Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy,No,Active Systemic Lupus Erythematosus (SLE),Yes,,,"Adult , Elderly","Female , Male"
8101,2018-002485-39,TAK-935-18-001,Interventional studies with investigational medicinal products,"Takeda Development Center Americas, Inc.","A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension 
Study To Assess the Long-Term Safety and Tolerability of Soticlestat (TAK935) as Adjunctive Therapy in Subjects With Developmental Epileptic 
Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, 
CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome 
(ENDYMION 1)",Active,,14/10/2019,04/11/2019,"A Phase 2, Prospective, Interventional, Open-Label, Multisite, Extension 
Study To Assess the Long-Term Safety and Tolerability of Soticlestat (TAK935) as Adjunctive Therapy in Subjects With Developmental Epileptic 
Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, 
CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome 
(ENDYMION 1) ",Yes,"Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut 
Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication 
Syndrome.",Yes,,,"Under 18 , Adult","Female , Male"
8121,2018-003342-16,20170703,Interventional studies with investigational medicinal products,Amgen Inc.,"A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache",Active,,06/11/2019,05/06/2020,A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache,No,Chronic migraine,,,Yes,"Adult , Elderly","Female , Male"
8142,2018-003180-54,20275,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 ,Ended,,19/08/2019,04/11/2019,Extension study to evaluate the long-term outcomes of subjects in study 20090 ,Yes,Retinopathy of prematurity   ,,Yes,,Under 18,"Female , Male"
8161,2019-000818-11,M-41008-48,Interventional studies with investigational medicinal products,"Almirall, S.A.",Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaque psoriasis (PHOTOSKILL),Active,,20/08/2019,10/12/2019,Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaque psoriasis (PHOTOSKILL),No,Moderate to severe chronic plaque psoriasis,,,Yes,"Adult , Elderly","Female , Male"
8181,2018-004175-12,B7931028,Interventional studies with investigational medicinal products,PFIZER INC,"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",Active,,01/08/2019,25/11/2019,A Phase 2b multicenter dose ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus,No,Systemic Lupus Erythematosus (SLE),Yes,,,"Adult , Elderly","Female , Male"
8201,2018-002303-33,EP0092,Interventional studies with investigational medicinal products,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
",Active,,27/09/2019,14/10/2019,"A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy
",No,"Focal-Onset Seizures
",,Yes,,"Adult , Elderly","Female , Male"
8221,2019-000810-12,CO41101,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
",Active,,11/10/2019,15/01/2020,A Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer,No,Metastatic triple-negative breast cancer (TNBC),,Yes,,"Adult , Elderly","Female , Male"
8261,2018-004889-34,NN7415-4311,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors,Active,,08/10/2019,25/11/2019,Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors,No,"Haemophilia A with inhibitors
Haemophilia B with inhibitors",,Yes,,"Under 18 , Adult , Elderly",Male
8281,2018-004002-25,CNTO1959UCO3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis",Active,,14/10/2019,06/05/2020,A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis,No,Moderately to Severely Active Ulcerative Colitis,Yes,Yes,,"Adult , Elderly","Female , Male"
8321,2018-000921-29,ALLN-177-302,Interventional studies with investigational medicinal products,"Allena Pharmaceuticals, Inc.","Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)",Not Commenced,,29/10/2019,04/12/2020,clinical research study to evaluate the efficacy and safety of reloxaliase in patients with enteric hyperoxaluria,No,Enteric Hyperoxaluria,,Yes,,"Adult , Elderly","Female , Male"
8341,2018-004530-14,1199-0337,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nintedanib of variable duration, in children and adolescents (6 to 17 year-old) with clinically significant fibrosing Interstitial Lung Disease.",Active,,02/10/2019,09/12/2019,A study to find out how nintedanib is taken up in the body and how well it is tolerated in children and adolescents with Interstitial Lung Disease (ILD).,Yes,Interstitial Lung Disease,,Yes,,Under 18,"Female , Male"
8381,2018-003289-15,0169,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A Phase 3, 4-week, Multicenter, Randomized, Double-blind,
Placebo-controlled, Parallel-group Study of TD-9855 in
Treating Symptomatic Neurogenic Orthostatic Hypotension in
Subjects With Primary Autonomic Failure",Not Commenced,,09/10/2019,13/01/2020,"This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson¿s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF)",No,Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure,,Yes,,"Adult , Elderly","Female , Male"
8382,2018-003941-41,0170,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic
Orthostatic Hypotension in Subjects with Primary Autonomic Failure",Active,,09/10/2019,03/02/2020,"This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson¿s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH)",No,Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure,,Yes,,"Adult , Elderly","Female , Male"
8401,2018-004565-14,20170625,Interventional studies with investigational medicinal products,Amgen Inc.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke",Active,,06/03/2020,05/05/2020,Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke,No,Dyslipidemia,,Yes,,"Adult , Elderly","Female , Male"
8441,2019-001164-30,TAS-120-201,Interventional studies with investigational medicinal products,Taiho Oncology Inc,A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,Active,,28/10/2019,07/02/2020,A study to evaluate the effects of TAS-120 in patients with Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,No,Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,Yes,,,"Adult , Elderly","Female , Male"
8501,2019-002488-91,MO39874,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF
ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATIVE BREAST CANCER",Active,,21/10/2019,04/11/2019,A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer in PD-L1-positive Population,No,Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC),,Yes,,"Adult , Elderly","Female , Male"
8541,2018-001006-28,20170770,Interventional studies with investigational medicinal products,Amgen Inc.,"PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",Active,,18/09/2019,03/03/2020,"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",No,"non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer",,Yes,,"Adult , Elderly","Female , Male"
8561,2018-002747-29,BIA-2093-213,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ",Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate,Active,,20/11/2019,02/03/2020,Prophylactic treatment of stroke patients with eslicarbazepine acetate to prevent the development of epilepsy ,No,Adult patients at high-risk to develop post-stroke epilepsy,Yes,,,"Adult , Elderly","Female , Male"
8581,2018-004301-32,TMC278HTX2002,Interventional studies with investigational medicinal products,Janssen Science Ireland UC,"A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed",Ended,,06/12/2019,03/02/2020,"A Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 years) who are Virologically Suppressed",Yes,HIV-1 Infection,Yes,,,Under 18,"Female , Male"
8601,2018-003987-29,APD334-303,Interventional studies with investigational medicinal products,"Arena Pharmaceuticals, Inc.",An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis,Active,,28/10/2019,20/04/2020,An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis,No,Ulcerative Colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
8681,2018-003986-33,APD334-302,Interventional studies with investigational medicinal products,"Arena Pharmaceuticals, Inc.","A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",Active,,28/10/2019,06/07/2020,A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitis,No,Ulcerative Colitis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
8701,2017-000419-17,AFT-38,Interventional studies with investigational medicinal products,"Alliance Foundation Trials, LLC","A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer",Active,,19/12/2019,03/02/2020,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbocicilb, to treat Metastatic Breast Cancer (PATINA)",No,"HER2 Positive Breast Cancer
Estrogen Receptor Positive Breast Cancer",,Yes,,"Adult , Elderly","Female , Male"
8721,2017-002992-25,20140346,Interventional studies with investigational medicinal products,Amgen Inc.,"RECITE: A Phase 3 Randomized Placebocontrolled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced
Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer",Active,,01/10/2019,19/05/2020,"This study is to learn more about the study drug romiplostim in people with chemotherapy-induced thrombocytopenia (CIT) receiving chemotherapy for the treatment of gastrointestinal, pancreatic or colorectal cancer.",No,"gastrointestinal or colorectal adenocarcinoma, which includes cancers of the esophagus, stomach, colon, or rectum.",,Yes,,"Adult , Elderly","Female , Male"
8781,2019-001896-35,PUMA-NER-6203,Interventional studies with investigational medicinal products,"Puma Biotechnology, Inc",An Open-Label Phase 2 Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib,Active,,30/01/2020,04/03/2020,A Clinical Study to Investigate Colon Pathology in Patients With Breast Cancer And HER2 Overexpression When Treated With Neratinib,No,HER2 amplified (HER2+) stage 1 through stage 4 primary adenocarcinoma of the breast,Yes,,,"Adult , Elderly","Female , Male"
8841,2019-001698-10,ION-682884-CS3,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc","A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",Active,,17/03/2020,23/03/2020,Study to determine the effectiveness and safety of ION-682884 in patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy,No,Hereditary Transthyretin-Mediated Amyloid Polyneuropathy,,Yes,,"Adult , Elderly","Female , Male"
8861,2019-001458-24,ALN-TTR02-011,Interventional studies with investigational medicinal products,"Alnylam Pharmaceuticals, Inc.","APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)",Ended,,22/11/2019,04/03/2020,A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy,No,Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy),,Yes,,"Adult , Elderly","Female , Male"
8881,2019-001876-12,LPRI-424/301,Interventional studies with investigational medicinal products,CHEMO RESEARCH SL.,"A multicentre, uncontrolled trial on the contraceptive efficacy, safety, tolerability and pharmacokinetics of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during 13 cycles",,,27/12/2019,25/05/2020,"A clinical study for testing the contraceptive efficacy, safety, tolerability and pharmacokinetics of dienogest 2 mg / ethinyl estradiol 0.02 mg during 13 cycles",Yes,Oral contraception for females aged 15-45,,Yes,,"Under 18 , Adult",Female
8922,2018-003837-13,ROPPET-NAF,Interventional studies with investigational medicinal products,"CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E",Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT,Not Commenced,,18/02/2020,20/04/2020,Statin effect on atheroma calcification,No,"Atherosclerosis, namely in the aorta, carotid and coronary arteries",,,Yes,"Adult , Elderly","Female , Male"
8941,2018-004891-36,NN7415-4307,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors,Active,,20/12/2019,02/03/2020,Research study to look at how well the drug concizumab works in your body if you have haemophilia without inhibitors,No,"Haemophilia A
Haemophilia B",,Yes,,"Under 18 , Adult , Elderly",Male
8961,2019-002006-51,MK-3475-975,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)",Active,,06/02/2020,23/03/2020,Placebo-controlled Trial of Pembrolizumab in Esophageal Carcinoma Participants Receiving Concurrent dCRT,No,Esophageal Carcinoma,,Yes,,"Adult , Elderly","Female , Male"
9021,2019-001845-42,TAK-788-3001,Interventional studies with investigational medicinal products,"Millennium Pharmaceuticals, Inc",A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,Active,,02/03/2020,23/03/2020,TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for NSCLC With EGFR Exon 20 Insertions,No,Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 20 insertion mutations,,Yes,,"Adult , Elderly","Female , Male"
9041,2019-001273-81,EFC15858,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors",Not Commenced,,11/02/2020,03/02/2020,"SAR408701 versus docetaxel in previously treated, Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) positive metastatic non-squamous non-small cell lung cancer patients ",No,Non-small cell lung cancer metastatic,,Yes,,"Adult , Elderly","Female , Male"
9081,2018-001795-38,ALLTogether1,Interventional studies with investigational medicinal products,Karolinska University Hospital,"ALLTogether1¿ A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
",Not Commenced,,17/04/2020,29/04/2022,A study protocol for children and young adults 1-45 years of age with newly diagnosed acute lymphoblastic leukaemia (ALL),No,Acute lymphoblastic leukaemia (ALL),,Yes,,"Under 18 , Adult","Female , Male"
9101,2019-003153-28,ALN-TTRSC02-003,Interventional studies with investigational medicinal products,"Alnylam Pharmaceuticals, Inc.","HELIOS-B:  A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy",Not Commenced,,08/01/2020,23/03/2020,A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy,No,Transthyretin Amyloidosis with Cardiomyopathy  (ATTR Amyloidosis with Cardiomyopathy),,Yes,,"Adult , Elderly","Female , Male"
9121,2017-001418-27,20150168,Interventional studies with investigational medicinal products,Amgen Inc.,"A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)",Active,,05/03/2020,03/02/2020,"This trial is designed to determine what effects the investigational medicine, ABP 959, has on the human body, and what effects the body has on the
investigational medicine after you have been given it, and if this is
comparable to what is seen for the licensed medicine, eculizumab, in
patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
This study will assess if the investigational medicine is safe and effective in
treating PNH compared to the licensed medicine.",No,Paroxysmal Nocturnal Hemoglobinuria (PNH),,Yes,,"Adult , Elderly","Female , Male"
9141,2019-002455-42,WO41554,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER",Active,,27/08/2020,20/04/2020,"A Study Evaluating the Efficacy and Safety of INAVOLISIB Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.",No,Breast cancer,,Yes,,"Adult , Elderly","Female , Male"
9181,2019-002375-34,EFC15299,Interventional studies with investigational medicinal products,Genzyme Corporation,"A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2 gangliosidosis (Tay-Sachs disease and Sandhoff disease) together with a separate basket for juvenile/adolescent late-onset GM2 gangliosidosis and ultra-rare diseases within the same and similar glucosylceramide-based sphingolipid pathway",Not Commenced,,11/12/2019,26/06/2020,"A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, and safety of venglustat in late-onset GM2",No,"Tay-Sachs disease
Sandhoff disease",,Yes,,"Under 18 , Adult","Female , Male"
9221,2018-004156-37,ND0612-317,Interventional studies with investigational medicinal products,NeuroDerm Ltd.,"A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson¿s disease experiencing motor fluctuations (BouNDless)",Not Commenced,,16/01/2020,26/06/2020,"A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson¿s disease (BouNDless)",No,Parkinson's disease,,Yes,,"Adult , Elderly","Female , Male"
9241,2018-000821-29,SPD503-401,Interventional studies with investigational medicinal products,"Takeda Development Center Americas, Inc.","A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized,
Double-blind, Parallel-group, Placebo-controlled, Active-comparator,
Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation
to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with
Attention-deficit/Hyperactivity Disorder",Active,,10/02/2020,13/11/2020,A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHD ,No,Attention-deficit/hyperactivity disorder (ADHD),,,Yes,Under 18,"Female , Male"
9242,2019-002835-27,ION-682884-CS2,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc","A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",Active,,30/03/2020,23/03/2020,A global trial to determine the effectiveness and safety of ION-682884 in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM),No,Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM),,Yes,,"Adult , Elderly","Female , Male"
9243,2017-003703-22,P2-IMU-838-UC,Interventional studies with investigational medicinal products,Immunic AG,"A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe ulcerative colitis CALDOSE-1",Active,,11/02/2020,12/03/2020,Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (CALDOSE-1),No,Ulcerative Colitis,Yes,,,"Adult , Elderly","Female , Male"
9281,2019-003051-11,HEP102,Interventional studies with investigational medicinal products,Promethera Therapeutics S.A.,"Randomized, placebo-controlled, double blind, multi-centre Phase IIb
study to evaluate the efficacy and safety of HepaStem in patients with
Acute on Chronic Liver Failure (ACLF) - DHELIVER",Not Commenced,,10/02/2020,09/06/2020,"This trial will evaluate the safety and efficacy of HepaStem compared to
placebo in patients with a cirrhotic liver condition called Acute on Chronic
Liver Failure (ACLF). The study will be performed in multiple centers and in
a double-blinded manner, meaning neither the patients nor the treating
physicians know who is on placebo or the study drug.",No,"Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF), ACLF combines an acute deterioration of liver function in an individual with pre-existing chronic liver disease and extrahepatic organ failures characterized by high short-term mortality (30-40% at 28days).
The development of ACLF is associated with exacerbated systemic inflammation that may indeed cause organ failures.",Yes,,,"Adult , Elderly","Female , Male"
9301,2019-003431-33,19766,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke",Active,,10/03/2020,24/04/2020,Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain.,No,Non-cardioembolic ischemic stroke,Yes,,,"Adult , Elderly","Female , Male"
9362,2018-003791-12,MK-7902-008,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)",Not Commenced,,29/05/2020,30/08/2021,Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy,No,NSCLC with squamous or nonsquamous histology,,Yes,,"Adult , Elderly","Female , Male"
9381,2019-000588-26,MK-8591A-019,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL",Not Commenced,,13/03/2020,04/05/2020,Doravirine/Islatravir in heavily treatment-experienced participants,No,HIV-1 infection,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
9401,2019-002263-99,209229,Interventional studies with investigational medicinal products,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",Active,,15/04/2020,20/04/2020,"A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancer
",No,Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,Yes,Yes,,"Adult , Elderly","Female , Male"
9421,2019-001877-97,LPRI-424/302,Interventional studies with investigational medicinal products,CHEMO RESEARCH SL.,"A multicentre, double-blind, double-dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mg",Active,,08/04/2020,29/06/2020,"A clinical study for testing the contraceptive efficacy, tolerability and safety of dienogest 2 mg / ethinyl estradiol 0.02 mg during nine cycles in comparison with drospirenone 3 mg / ethinyl estradiol 0.02 mg",No,Oral contraception for females aged 18-45,,Yes,,Adult,Female
9441,2019-003463-22,CLOTOT3-16IA03,Interventional studies with investigational medicinal products,"Laboratorios Salvat, S.A.","A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Clotrimazole 1% Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis).",Not Commenced,,12/03/2020,23/03/2020,Clinical Trial to Assess the Efficacy and Safety of Clotrimazole 1% Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis).,No,Fungal Otitis Externa (Otomycosis),,Yes,,"Adult , Elderly","Female , Male"
9461,2019-003230-17,CAIN457M2301E1,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa",Active,,30/03/2020,05/06/2020,"A clinical trial to evaluate long-term treatment with a drug called secukinumab in
adult patients who are diagnosed with moderate to severe hidradenitis
suppurativa (long term skin disease characterized by the occurrence of
inflamed and swollen lumps) and that participated in the previous clinical studies named ""CAIN457M2301"" and ""CAIN457M2302"".
",No,hidradenitis suppurativa,,Yes,,"Adult , Elderly","Female , Male"
9481,2019-004023-20,MK-3475-992,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)",Active,,16/04/2020,08/05/2020,Chemoradiotherapy +/- pembrolizumab in participants with MIBC,No,Muscle Invasive Bladder Cancer,,Yes,,"Adult , Elderly","Female , Male"
9521,2018-002553-30,EORTC-1745-ETF-BCG,Interventional studies with investigational medicinal products,European Organization for Research and Treatment of Cancer,A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES),Active,,30/03/2020,23/03/2020,A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapse,No,Localized ER+ breast cancer,Yes,,,Elderly,"Female , Male"
9541,2017-002456-88,Stroke34,Interventional studies with investigational medicinal products,"CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E",STROKE34: randomized controlled phase IIa trial of intra-arterial CD34+ cells in acute ischemic stroke.,Not Commenced,,28/02/2023,18/06/2021,STROKE34: clinical trial to evaluate the efficacy of an autotransplant of stem cells (CD34+) administered after an acute ischemic stroke.,No,Acute ischemic stroke,Yes,,,"Adult , Elderly","Female , Male"
9561,2019-002817-21,AC-065A310,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged greater or equal than 2 to under 18 years with Pulmonary Arterial Hypertension.",Active,,03/07/2020,13/08/2020,A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.,Yes,Pulmonary Arterial Hypertension,,Yes,,Under 18,"Female , Male"
9601,2018-003243-39,ALXN1210-MG-306,Interventional studies with investigational medicinal products,"Alexion Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis",Active,,11/05/2020,21/07/2020,Study to evaluate the safety and efficacy of ravulizumab in adult patients with generalized Myasthenia Gravis who have never been treated with a complement inhibitor.,No,Generalized Myasthenia Gravis,,Yes,,"Adult , Elderly","Female , Male"
9621,2018-003135-30,URO-901-3005,Interventional studies with investigational medicinal products,Urovant Sciences GmbH,"A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)",Active,,31/03/2020,04/05/2020,Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptoms,No,Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH) ,,Yes,,"Adult , Elderly",Male
9661,2018-002697-45,ACT15378,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric
Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia In First or Second Relapse",Not Commenced,,02/06/2020,15/06/2020,Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia,Yes,"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination with Chemotherapy in Pediatric Patients from 28 Days to Less than 18 Years of Age with Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse",Yes,,,Under 18,"Female , Male"
9681,2019-003706-27,D8530C00002,Interventional studies with investigational medicinal products,AstraZeneca AB,"SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer",Active,,17/06/2020,27/07/2020,SERENA-2: A Randomised Comparative Phase 2 Study of AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer,No,Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer,Yes,,,"Adult , Elderly",Female
9701,2019-002075-33,ENRICH-AF,Interventional studies with investigational medicinal products,Hamilton Health Sciences Corporation through its Population Health Sciences Institute,Edoxaban for intracranial hemorrhage survivors with atrial fibrillation,Not Commenced,,27/04/2020,09/04/2021,Reduction in the risk of stroke in people who have both a previous intracranial bleed and atrial fibrillation,No,High risk atrial fibrillation patients with previous intracranial hemorrhage,,,Yes,"Adult , Elderly","Female , Male"
9721,2019-003801-90,EFC16460,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable",Not Commenced,,03/03/2020,20/04/2020,"Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable",No,Prurigo Nodularis,,Yes,,"Adult , Elderly","Female , Male"
9741,2019-003582-18,20190009,Interventional studies with investigational medicinal products,Amgen Inc.,"A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C",Active,,05/05/2020,15/06/2020,A Phase 3 Study to Compare AMG 510 With Docetaxel in NSCLC Subjects With KRAS p.G12C Mutation (CodeBreak 200),No,"Previously treated locally advanced and unresectable or metastatic nonsmall
cell lung cancer (NSCLC) with KRAS p.G12C mutation",,Yes,,"Adult , Elderly","Female , Male"
9761,2019-002425-30,0171,Interventional studies with investigational medicinal products,Theravance Biopharma Ireland Limited,"A Phase 3, 182-week, Open-Label, Extension Study to Investigate the
Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic
Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary
Autonomic Failure",Active,,31/03/2020,25/05/2020,"Phase 3 Open-Label Extension Study of TD-9855 for Treating symptomatic
nOH in Subjects with Primary Autonomic Failure",No,Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure,,Yes,,"Adult , Elderly","Female , Male"
9801,2019-004066-18,AL001-3,Interventional studies with investigational medicinal products,Alector Inc.,"A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene",Active,,29/05/2020,02/06/2020,"A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD",No,Frontotemporal Dementia,,Yes,,"Adult , Elderly","Female , Male"
9823,2019-002575-34,19733,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 12-week treatment period.",Active,,27/06/2020,24/06/2020,Clinical study to evaluate the treatment effect and safety of BAY1817080 in patients with overactive bladder (OAB),No,Overactive bladder,Yes,,,"Adult , Elderly","Female , Male"
9841,2019-003211-57,CAIN457Q12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis",Active,,26/06/2020,13/08/2020,"A clinical trial to evaluate the safety, efficacy, and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis",No,Lupus Nephritis,,Yes,,"Adult , Elderly","Female , Male"
9881,2019-002345-37,MK7902-012,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)",Active,,29/04/2020,04/05/2020,Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma,No,Incurable/Non-metastatic Hepatocellular Carcinoma,,Yes,,"Adult , Elderly","Female , Male"
9901,2019-001076-11,CTQJ230A12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease (CVD). ",Ended,,17/06/2020,25/05/2020,A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with cardiovascular disease. ,No,Cardiovascular Disease,,Yes,,"Adult , Elderly","Female , Male"
9921,2019-002469-37,CA2097FL,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
(CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)",Not Commenced,,11/09/2020,27/07/2020,"A Clinical Trial for Newly Diagnosed High Risk Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",No,"Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",,Yes,,"Adult , Elderly","Female , Male"
9981,2019-000413-36,BGB-3111-306,Interventional studies with investigational medicinal products,"BeiGene, Ltd.","A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation",Active,,26/05/2020,27/07/2020,Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation,No,Mantle Cell Lymphoma,,Yes,,"Adult , Elderly","Female , Male"
10001,2019-003914-15,ACT16525,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non¿small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors, previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor",Not Commenced,,21/07/2020,15/06/2020,SAR408701 in combination with ramucirumab in pre-treated patients with non squamous non-small cell lung cancer (NSQ NSCLC) ,No,Non-small cell lung cancer metastatic,Yes,,,"Adult , Elderly","Female , Male"
10061,2018-003585-14,D-US-60010-001,Interventional studies with investigational medicinal products,"Ipsen Bioscience, Inc.","An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas",Active,,04/05/2020,16/07/2020,"Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard chemotherapy in patients with pancreatic cancer",No,"Previously Untreated, Metastatic Pancreatic Adenocarcinoma",,Yes,,"Adult , Elderly","Female , Male"
10081,2019-001862-13,AB19001,Interventional studies with investigational medicinal products,AB Science,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)",Not Commenced,,07/10/2020,08/07/2022,Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS),No,patients suffering from Amyotrophic Lateral Sclerosis (ALS),,Yes,,"Adult , Elderly","Female , Male"
10101,2019-001341-40,COMB157G23101,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod ",Active,,14/05/2020,26/06/2020,An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approved therapies or fingolimod to ofatumumab ,No,Multiple sclerosis,,Yes,,Adult,"Female , Male"
10121,2019-002089-11,CMBG453B12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)",Ended,,30/06/2020,06/07/2020,"A study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2)",No,"adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2)",,Yes,,"Adult , Elderly","Female , Male"
10141,2018-002851-14,QUIWI,Interventional studies with investigational medicinal products,FUNDACIÓN PETHEMA,A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML,Not Commenced,,18/06/2020,27/07/2020,CIinical trial to compare the efficacy and safety of chemotherapy plus quizartinib versus chemotherapy plus placebo in patients with acute myeloid leukemia without FLT3 mutation,No,Acute myeloid leukemia,Yes,,,"Adult , Elderly","Female , Male"
10161,2018-004648-44,MedOPP253,Interventional studies with investigational medicinal products,MedSIR (Medica Scientia Innovation Research),"A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of                                    Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pretreated    unresectable locally advanced or metastatic triple-negative breast cancer patients (PATHFINDER",Active,,19/06/2020,06/07/2020,Clinical trial with Ipatasertib in combination with chemoterapy agents for unresectable locally advanced or metastatic triple-negative breast cancer patients,No,UNRESECTABLE LOCALLY ADVANCED OR METASTATIC RIPLE-NEGATIVE BREAST CANCER PATIENTS,Yes,,,"Adult , Elderly",Female
10261,2018-004687-64,D3614C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer(TNBC)
(CAPItello-290)",Active,,14/08/2020,01/10/2020,Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer,No,Triple-negative Breast Cancer,,Yes,,"Adult , Elderly","Female , Male"
10281,2018-001954-91,EFC15805,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation",Not Commenced,,24/04/2020,15/06/2020,"Pivotal study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate to severe COPD with Type 2 inflammation",No,Chronic obstructive pulmonary disease,,Yes,,"Adult , Elderly","Female , Male"
10301,2019-000721-50,INCB54828-205,Interventional studies with investigational medicinal products,Incyte Corporation,"A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)",Not Commenced,,22/07/2020,31/08/2020,"A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)",No,Male and female participants at least 18 years of age who have untreated metastatic or unresectable urothelial carcinoma.,Yes,,,"Adult , Elderly","Female , Male"
10341,2019-004368-22,221AD304,Interventional studies with investigational medicinal products,Biogen Idec Research Limited,"Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer¿s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",Active,,03/06/2020,06/07/2020,"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer¿s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",No,Alzheimer's Disease ,,Yes,,"Adult , Elderly","Female , Male"
10361,2016-004558-13,Z7224L02,Interventional studies with investigational medicinal products,Zambon SpA,"A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)",Ended,,27/07/2020,07/08/2020,"A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)",No,Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa ,,Yes,,"Adult , Elderly","Female , Male"
10381,2019-004647-74,LPS15834,Interventional studies with investigational medicinal products,sanofi-aventis groupe,"Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma",Not Commenced,,13/05/2020,09/09/2020,The effect of dupilumab on lung function and related changes in airway volumes detectable by functional respiratory imaging in patients with moderate-severe asthma ,No,Asthma,,,Yes,Adult,"Female , Male"
10441,2019-003851-12,20968,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",Ended,,01/07/2020,15/06/2020,Study to gather information on safety and use of high dose aflibercept injection into the eye in patients with an age related eye disorder that causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid into the light sensitive lining inside the eye,No,Neovascular Age-Related Macular Degeneration,,Yes,,"Adult , Elderly","Female , Male"
10461,2020-000402-29,GR41987,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA",Active,,26/05/2020,15/06/2020,A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema,No,Diabetic Macular Edema (DME),,Yes,,"Adult , Elderly","Female , Male"
10481,2019-002463-10,BO42864,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER",Active,,30/06/2020,14/01/2021,A study comparing pralsetinib to a standard of care in patients with lung cancer,No,"RET fusion-positive, Metastatic Non-Small Cell Lung Cancer",,Yes,,"Adult , Elderly","Female , Male"
10501,2019-002533-11,AC-055-315,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment
Period With Macitentan 75 mg.",Active,,07/07/2020,31/08/2020,A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension.,No,Pulmonary arterial hypertension,,Yes,,"Adult , Elderly","Female , Male"
10521,2020-001348-25,COMP004,Interventional studies with investigational medicinal products,"COMPASS Pathways, Ltd",A multicentre study to assess safety and efficacy of psilocybin in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU),Not Commenced,,08/07/2020,06/07/2020,Long Term Follow up study for subjects that participated in COMP001 and COMP003 trial,No,Treatment-Resistant Depression (P-TRD),Yes,,,"Adult , Elderly","Female , Male"
10561,2020-001366-11,Solidarity-Plus,Interventional studies with investigational medicinal products,AICIB - Agência de Investigação Clínica e Inovação Biomédica,"An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care



",Active,,07/05/2020,20/05/2020,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,No,COVID-19,,Yes,,"Adult , Elderly","Female , Male"
10562,2020-000306-29,20103,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ¿ 40% (LVEF ¿ 40%).",Active,,09/06/2020,31/08/2020,A study to gather information on the influence of  study drug finerenone  on the number of deaths and hospitalizations in participants with heart failure.,No,Heart failure,,Yes,,"Adult , Elderly","Female , Male"
10581,2019-000710-11,SOLTI-1718,Interventional studies with investigational medicinal products,SOLTI,Targeting EGFR/ERBB2 with Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial),Active,,11/09/2020,31/08/2020,Clinical study with Neratinib in Metastatic breast cancer,No,Pre and post-menopausal women and men with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer,Yes,,,"Adult , Elderly","Female , Male"
10601,2020-000100-11,GO41892,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL,  CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF  TEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY",Active,,17/07/2020,31/08/2020,Study of Atezolizumab in Combination with Cabozantinib Versus Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy,No,Non-small cell lung cancer (NSCLC),,Yes,,"Adult , Elderly","Female , Male"
10621,2019-004084-49,TAS-120-202,Interventional studies with investigational medicinal products,Taiho Oncology Inc,A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS ,Active,,22/07/2020,12/10/2020,A study of futibatinib in patients with FGFR gene-modified cancers,No,Fibroblast growth factor receptor (FGFR) aberrations,Yes,,,Adult,"Female , Male"
10641,2019-001739-29,MedOPP243,Interventional studies with investigational medicinal products,MedSIR (Medica Scientia Innovation Research),"A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor2 (HER2)-Positive Advanced Breast Cancer with Brain Metastases and/or Leptomeningeal Carcinomatosis",Not Commenced,,04/02/2021,09/06/2021,Breast cancer patiens with brain metastasis,No,"Pretreated, unresectable locally advanced or metastatic Human Epidermal Growth
Factor Receptor 2 (HER2)-positive or HER2-low expressing breast cancer (BC) with
untreated or treated brain metastases (BMs) or leptomeningeal carcinomatosis
(LMC).
",Yes,,,"Adult , Elderly","Female , Male"
10701,2016-005119-42,MO39193,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALLY ADVANCED OR METASTATIC) TRIPLE-NEGATIVE BREAST CANCER",Active,,30/07/2020,31/08/2020,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients with Early Relapsing Recurrent Triple-Negative Breast Cancer,No,Triple-Negative Breast Cancer (TNBC),,Yes,,"Adult , Elderly","Female , Male"
10721,2019-004980-36,MS200527-0082,Interventional studies with investigational medicinal products,Merck Healthcare KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.",Active,,12/08/2020,06/01/2021,Evobrutinib compared to Teriflunomide in participants with Relapsing Multiple Sclerosis,No,Relapsing Multiple Sclerosis,,Yes,,Adult,"Female , Male"
10761,2020-001747-21,ISPUP2020CT1,Interventional studies with investigational medicinal products,Instituto de Saúde Pública da Universidade do Porto,Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial ,Not Commenced,,29/06/2020,06/08/2020,Efficacy and safety of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19),No,Novel coronavirus pneumonia (COVID-19),,,Yes,Adult,"Female , Male"
10781,2019-002754-22,TCC-201,Interventional studies with investigational medicinal products,Ascendis Pharma Growth Disorders A/S,"ACcomplisH: A Phase 2, multicenter, double-blind, randomized, placebo-controlled, dose escalation trial evaluating safety, efficacy, and pharmacokinetics of subcutaneous doses of TransCon CNP administered once weekly for 52 weeks in prepubertal children with achondroplasia followed by an Open-Label Extension Period",Not Commenced,,27/08/2020,05/02/2021,"A Phase 2 study to evaluate the safety, efficacy and pharmacokinetics of TransCon CNP in prepubertal children with achondroplasia followed by an Open-Label Extension Period",No,Achondroplasia (ACH) in prepubertal children,Yes,,,Under 18,"Female , Male"
10801,2019-004749-33,1381-0011,Interventional studies with investigational medicinal products,Unilfarma - União Internacional Laboratórios Farmacêuticos Lda.,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",Not Commenced,,09/09/2020,06/07/2020,A study to test BI 754091 alone or in combination with BI 836880 in people who have advanced anal cancer,No,metastatic squamous cell carcinoma of the anal canal,Yes,,,"Adult , Elderly","Female , Male"
10821,2020-000440-63,GR41984,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
",Active,,03/08/2020,31/08/2020,A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion,No,Macular edema secondary to Branch Retinal Vein Occlusion,,Yes,,"Adult , Elderly","Female , Male"
10822,2020-000441-13,GR41986,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION
",Active,,03/08/2020,31/08/2020,A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion,No,Macular edema secondary to Central Retinal or Hemiretinal Vein Occlusion,,Yes,,"Adult , Elderly","Female , Male"
10841,2018-004670-10,AG10-333,Interventional studies with investigational medicinal products,"Eidos Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)",Not Commenced,,10/08/2020,16/11/2020,Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy  (ATTR-PN),Yes,Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN),,Yes,,"Adult , Elderly","Female , Male"
10901,2019-004297-26,C19-29,Interventional studies with investigational medicinal products,INSERM - Institut National de la Santé et de la Recherche Médicale,Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen,Not Commenced,,08/06/2020,27/07/2020,Prophylactic treatment of the ductus arteriosus in preterm infants by paracetamol,No,Patent ductus arteriosus,Yes,Yes,,Under 18,"Female , Male"
10921,2018-004362-34,CA209-8TT,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab,Not Commenced,,27/07/2020,31/08/2020,Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combination,No,pan tumor,Yes,,,"Adult , Elderly","Female , Male"
10941,2019-004773-29,GO41854,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND  TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION.",Active,,27/07/2020,31/08/2020,"A Study of Atezolizumab and Tiragolumab compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non¿Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-based Chemoradiation.",No,Non¿small cell lung cancer (NSCLC),,Yes,,"Adult , Elderly","Female , Male"
10981,2019-002992-33,54135419TRD3013,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor",Ended,,08/10/2020,23/10/2020,A comparison of Esketamine Nasal Spray versus Quetiapine Extended-Release.,No,Treatment-Resistant Major Depressive Disorder,,Yes,,"Adult , Elderly","Female , Male"
11001,2019-003957-27,20115,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocimab to ESRD patients on regular hemodialysis",Ended,,10/08/2020,09/10/2020,Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysis,No,Prevention of thromboembolic events in ESRD patients on hemodialysis who are at risk for thromboembolic events,Yes,,,"Adult , Elderly","Female , Male"
11041,2020-000348-77,XL184-315,Interventional studies with investigational medicinal products,"Exelixis, Inc.","A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer ",Active,,27/08/2020,10/11/2020,Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer,No,Metastatic Castration-Resistant Prostate Cancer,,Yes,,"Adult , Elderly",Male
11061,2019-003509-80,IMGN853-0416,Interventional studies with investigational medicinal products,ImmunoGen Inc.,"MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression",Active,,07/08/2020,05/02/2021,"A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's
choice of cancer medicines in women with advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",No,"Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian
Tube Cancers with High Folate Receptor-Alpha Expression",,Yes,,"Adult , Elderly",Female
11081,2020-001178-31,YO42137,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY.",Active,,22/09/2020,21/09/2020,A Study of Atezolizumab with or without Tiragolumab (Anti-TIGIT Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy.,No,Esophageal squamous cell carcinoma,,Yes,,"Adult , Elderly","Female , Male"
11101,2019-004873-17,NBI-74788-CAH3003,Interventional studies with investigational medicinal products,Neurocrine Biosciences Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment",Not Commenced,,01/10/2020,23/11/2020,A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia,No,Classic Congenital Adrenal Hyperplasia (CAH),,Yes,,"Adult , Elderly","Female , Male"
11121,2018-002620-17,18-513,Interventional studies with investigational medicinal products,"Alexion Pharmaceuticals, Inc.",A RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR,Active,,28/08/2020,20/11/2020,A clinical trial to study the effect of andexanet alfa compared to the usual care with regards to stopping severe/life threatening bleeding in patients with bleeding inside the skull,No,Oral FXa inhibitor-treated patients with acute intracranial bleeding.,,,Yes,"Adult , Elderly","Female , Male"
11141,2020-000894-26,BN42083,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS",Active,,08/10/2020,04/12/2020,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis",No,Primary Progressive Multiple Sclerosis (MS),,Yes,,Adult,"Female , Male"
11161,2019-003406-27,SL0043,Interventional studies with investigational medicinal products,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",Not Commenced,,16/11/2020,14/12/2020,A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus,No,Systemic lupus erythematosus (SLE),,Yes,,"Under 18 , Adult , Elderly","Female , Male"
11181,2020-000893-69,BN42082,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS ",Active,,24/09/2020,04/12/2020,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis",No,Relapsing Multiple Sclerosis (MS),,Yes,,Adult,"Female , Male"
11221,2020-000936-23,C20-15,Interventional studies with investigational medicinal products,INSERM - Institut National de la Santé et de la Recherche Médicale,"Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults ",Active,,10/07/2020,11/08/2020,Safety and efficacy of treatments of COVID-19 in hospitalized adults (Discovery),No,"COVID-19 infection

",,Yes,,"Adult , Elderly","Female , Male"
11241,2019-004435-23,208379,Interventional studies with investigational medicinal products,ViiV Healthcare UK Limited,"A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcriptase inhibitors, in HIV-1 infected antiretroviral treatment-naive adults",Active,,25/11/2020,02/11/2020,A Phase 2b Dose-Range Finding Clinical Trial in HIV-1 Infected Treatment-Naive Adults,No,Human Immunodeficiency Virus Type-1 (HIV-1),Yes,,,"Adult , Elderly","Female , Male"
11242,2019-003618-15,BAY1841788/20321,Interventional studies with investigational medicinal products,Bayer Consumer Care AG,"An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies",Ended,,23/09/2020,21/09/2020,An open study for participants who have been on darolutamide treatment in any other Bayer study.,No,PROSTATE CANCER,,Yes,,"Adult , Elderly",Male
11261,2017-004417-42,MK3475-587,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.",Active,,01/09/2020,23/12/2020, Extension Study for Participants With Advanced Tumors in Pembrolizumab Trials,No,Advanced Tumors,,Yes,,"Adult , Elderly","Female , Male"
11281,2020-000743-31,73841937NSC3003,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Active,,23/12/2020,04/02/2021,A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,No,EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer,,Yes,,"Adult , Elderly","Female , Male"
11321,2018-002952-34,NN9924-4437,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes,Active,,31/08/2020,15/01/2021,A research study to compare a new medicine oral semaglutide to a dummy medicine in children and teenagers with type 2 diabetes,Yes,"Diabetes Mellitus, Type 2",,Yes,,Under 18,"Female , Male"
11322,2020-003057-30,20190370,Interventional studies with investigational medicinal products,Amgen Inc.,Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF,Ended,,13/11/2020,12/10/2020,Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF,No,Chronic heart failure with reduced ejection fraction,,Yes,,"Adult , Elderly","Female , Male"
11341,2018-002364-44,IELSG47,Interventional studies with investigational medicinal products,IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas,Active,,07/10/2020,13/01/2021,Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas,No,Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment,Yes,,,"Adult , Elderly","Female , Male"
11381,2012-000566-38,UC-0160/1202_/_GETUG-AFU_23,Interventional studies with investigational medicinal products,UNICANCER,"A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse",Not Commenced,,31/03/2021,19/03/2021,_,No,localized prostate cancer with high-risk features of relapse,,Yes,,"Adult , Elderly",Male
11441,2020-001578-31,CINC280A2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation (MET¿ex14)",Ended,,27/10/2020,14/12/2020,Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.,No,cMET mutated NSCLC,,Yes,,"Adult , Elderly","Female , Male"
11461,2020-001217-20,LPS16677,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma",Not Commenced,,17/11/2020,23/11/2020,Dupilumab asthma sleep study,No,Asthma,,,Yes,Adult,"Female , Male"
11481,2020-001496-32,KB070,Interventional studies with investigational medicinal products,Kedrion S.p.A,"A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)",Not Commenced,,11/05/2021,19/03/2021,"Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)",Yes,Pediatric Patients Affected by Primary Immunodeficiency Disease.,,Yes,,Under 18,"Female , Male"
11501,2020-000917-34,20-214-29/CA045-022,Interventional studies with investigational medicinal products,Nektar Therapeutics,"A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)",Active,,11/09/2020,28/11/2020,A study of bempegaldesleukin plus nivolumab versus nivolumab alone after surgical removal of all known Melanoma lesions in patients at high risk of cancer returning after surgery,Yes,Resected Stage IIIA (lymph node metastasis > 1 mm)/B/C/D and IV melanoma with no evidence of disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
11521,2020-000766-42,WN42171,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB
ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE",Active,,30/10/2020,13/01/2021,"An Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants with Alzheimer's Disease",No,Alzheimer's Disease,,Yes,,"Adult , Elderly","Female , Male"
11541,2020-000377-25,MS202359_0006,Interventional studies with investigational medicinal products,Merck Healthcare KGaA,"A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)",Not Commenced,,17/08/2020,12/03/2021,A clinical trial in patients with head and neck cancer of Debio 1143 in combination with platinum-based  chemotherapy and radiotherapy ,No,Locally advanced squamous cell carcinoma of the head and neck (SCCHN),,Yes,,"Adult , Elderly","Female , Male"
11561,2017-000236-34,ELAN,Interventional studies with investigational medicinal products,Inselspital (University Hospital) Bern,"Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial",Not Commenced,,26/10/2020,28/09/2021,"Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial",No,Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke,,,Yes,"Adult , Elderly","Female , Male"
11621,2019-001755-39,ACE-LY-312(D8227C00001),Interventional studies with investigational medicinal products,Acerta Pharma B.V. (A Member of the AstraZeneca Group),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ¿75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma.",Active,,30/10/2020,20/11/2020,A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL,No,Diffuse large B-cell lymphoma,,Yes,,"Adult , Elderly","Female , Male"
11641,2020-001824-33,EFC15935,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A randomized, multicenter, double-blind phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease",Not Commenced,,15/12/2020,15/01/2021,Amcenestrant (SAR439859) plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancer ,No,"ER (+), HER2 (-) breast cancer",,Yes,,"Adult , Elderly","Female , Male"
11701,2020-000644-55,EFC16034,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis ",Not Commenced,,21/09/2020,14/01/2021,Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2),No,Relapsing Multiple Sclerosis,,Yes,,Adult,"Female , Male"
11721,2020-000647-30,EFC16645,Interventional studies with investigational medicinal products,Genzyme Corporation,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis",Not Commenced,,22/09/2020,26/02/2021,Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES),No,Non-relapsing Secondary Progressive Multiple Sclerosis,,Yes,,Adult,"Female , Male"
11761,2020-002349-40,CRTH258A2303E1,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular Age-related Macular Degeneration who have completed the CRTH258A2303 (TALON) study",Active,,25/11/2020,15/01/2021,"An extension study assessing the efficacy and safety of brolucizumab in a Treat-to-Control regimen in patients with neovascular Age-related Macular Degeneration (nAMD), also commonly referred to as wet AMD, who have completed the CRTH258A2303 (TALON) study",No,neovascular Age-related Macular Degeneration,,Yes,Yes,"Adult , Elderly","Female , Male"
11781,2020-001175-32,BIA-91067-404,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson¿s disease patients with end-of-dose motor fluctuations and associated pain.",Active,,23/12/2020,15/01/2021,Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson¿s disease,No,Parkinson's disease patients with wearing-off motor fluctuations and associated pain.,,,Yes,"Adult , Elderly","Female , Male"
11801,2020-001189-13,C4181005,Interventional studies with investigational medicinal products,PFIZER INC,"A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY,  PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",Active,,26/11/2020,16/03/2021,"Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasia",No,Achondroplasia,Yes,,,Under 18,"Female , Male"
11841,2020-000633-40,61186372NSC3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Active,,08/04/2021,23/04/2021,"A Clinical Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",No,EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer ,,Yes,,"Adult , Elderly","Female , Male"
11861,2018-004356-38,M19-388,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial,Active,,05/03/2021,21/05/2021,An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial,No,Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma; T prolymphocytic leukemia; Chronic myeloid leukemia; Waldenstrom's macroglobulinemia lymphoma and Relapsed/refractory pediatric malignancies; Acute Myelogenous Leukemia (AML),,Yes,,"Under 18 , Adult , Elderly","Female , Male"
11922,2020-003079-16,INS-416,Interventional studies with investigational medicinal products,Insmed Incorporated,"ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)",Not Commenced,,30/12/2020,03/06/2022,A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused by MAC,No,Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC),,Yes,,"Adult , Elderly","Female , Male"
11941,2017-000586-72,NMSG25/16,Interventional studies with investigational medicinal products,Oslo University Hospital,KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study,Not Commenced,,20/01/2021,15/01/2021,Kyprolis-Revlimid-dexamethasone consolidation treatment in myeloma patients with a positive PET-CT after standard first line treatment,No,Multiple Myeloma,Yes,,,"Adult , Elderly","Female , Male"
11981,2020-000119-66,BO41843,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER",Active,,11/02/2021,14/12/2020,"A Study to Evaluate the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",No,"First line of treatment for Estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer",,Yes,,"Adult , Elderly","Female , Male"
12003,2020-002209-25,67652000PCR3002,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",Active,,04/02/2021,26/02/2021,A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC),No,Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC),,Yes,,"Adult , Elderly",Male
12022,2020-003688-25,INS1007-301,Interventional studies with investigational medicinal products,Insmed Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis ¿ The ASPEN Study",Active,,07/01/2021,18/02/2021,A study to evaluate the effects of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis ¿ The ASPEN Study,Yes,Non-Cystic Fibrosis Bronchiectasis,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
12042,2019-002957-46,56021927PCR3015,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients.",Active,,10/02/2021,28/06/2021,A research study to assess the efficacy and safety of apalutamide in the treatment of high-risk Hormone-Sensitive Prostate Cancer assessed by an imaging scan.,No,High risk recurrent prostate cancer previously treated with radical prostatectomy,,Yes,,"Adult , Elderly",Male
12043,2019-004931-21,BO42162,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLEMENT INHIBITORS",Active,,19/05/2021,05/05/2021,A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously Treated with Complement Inhibitors,Yes,Paroxysmal Nocturnal Hemoglobinuria (PNH),,Yes,,Under 18,"Female , Male"
12062,2020-000645-14,EFC16035,Interventional studies with investigational medicinal products,Genzyme Corporation,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)",Active,,23/11/2020,26/02/2021,Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (PERSEUS),No,Primary Progressive Multiple Sclerosis ,,Yes,,Adult,"Female , Male"
12082,2020-001942-20,CCFZ533B2201E1,Interventional studies with investigational medicinal products,Novartis Pharma AG,A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren¿s Syndrome,Active,,31/03/2021,02/03/2021,Study of safety and tolerability of CFZ533 in patients with Sjögren¿s Syndrome,No,Sjögren syndrome,Yes,,,"Adult , Elderly","Female , Male"
12102,2019-004770-25,D7310C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor",Active,,31/03/2021,21/05/2021,Study of Monalizumab Given With Cetuximab or Placebo Given with Cetuximab in Patients With Head and Neck Cancer that has come back or spread to other parts of the body,No,Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor,,Yes,,"Adult , Elderly","Female , Male"
12162,2020-000798-26,20-AVP-786-306,Interventional studies with investigational medicinal products,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer¿s type.",Not Commenced,,03/02/2021,09/04/2021,"A study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer¿s type.",No,Agitation in patients with dementia of the Alzheimer¿s type,,Yes,,"Adult , Elderly","Female , Male"
12182,2019-004857-10,GN41851,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS",Active,,09/02/2021,05/02/2021,To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis,No,Relapsing multiple sclerosis (RMS),,Yes,,Adult,"Female , Male"
12202,2020-000454-10,NN1436-4478,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes treated with basal insulin",Not Commenced,,29/01/2021,15/01/2021,"A research study to compare two types of insulin, a new weekly insulin, insulin icodec and an available daily insulin, insulin degludec, in people with type 2 diabetes who use daily insulin",No,"Diabetes Mellitus, Type 2",,Yes,,"Adult , Elderly","Female , Male"
12222,2020-001847-16,BO41932,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL,Active,,21/06/2021,19/03/2021,"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting
Rational For You (Tapistry) Phase II Platform Trial",No,Solid tumors ,Yes,,,"Under 18 , Adult , Elderly","Female , Male"
12262,2020-002913-16,0135-0347,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","The TRISTARDS trial - ThRombolysIS Therapy for ARDS
A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by COVID-19.",Active,,17/12/2020,28/12/2020,The TRISTARDS trial - ThRombolysIS Therapy for ARDS A study to test whether different doses of alteplase help people with severe breathing problems because of COVID 19.,No,Acute respiratory distress syndrome caused by Covid-19,Yes,Yes,,"Under 18 , Adult , Elderly","Female , Male"
12322,2020-003681-40,WO42633,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY.",Active,,23/02/2021,19/03/2021,A Study to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence.,No,Early human epidermal growth factor receptor 2 (HER2) positive breast cancer. ,,Yes,,"Adult , Elderly","Female , Male"
12342,2020-002464-31,KRT-232-111,Interventional studies with investigational medicinal products,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia",Not Commenced,,01/04/2021,19/03/2021,A study to evaluate the safety and efficacy of KRT-232 in combination with Acalabrutinib in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia. ,No,"- Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL)
- R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhibitor
- R/R DLBCL with non-germinal center B-cell like(GCB) subtype
- R/R DLBCL with double-expressor lymphoma subtype",Yes,,,"Adult , Elderly","Female , Male"
12362,2020-002620-36,17000139BLC3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy",Not Commenced,,18/06/2021,25/05/2021,"A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy",No,Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder,,Yes,,"Adult , Elderly","Female , Male"
12382,2020-002646-16,17000139BLC2001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy",Active,,18/06/2021,01/06/2021,"Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guerin who are Ineligible for or Elected Not to Undergo Radical Cystectomy",No,Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder,Yes,,,"Adult , Elderly","Female , Male"
12402,2020-000597-26,BO42161,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS ",Active,,18/05/2021,30/04/2021,A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated with Complement Inhibitors.,No,PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
12442,2020-001872-13,PTC299-VIR-015-COV19,Interventional studies with investigational medicinal products,"PTC Therapeutics, Inc.",Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with COVID-19 (FITE19),Active,,06/01/2021,15/01/2021,Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with COVID-19 (FITE19),No,Coronavirus disease 2019 (COVID-19),Yes,Yes,,"Adult , Elderly","Female , Male"
12482,2020-000791-38,WA42293,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS",Active,,17/12/2020,19/03/2021,A Study to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis,No,Idiopathic pulmonary fibrosis (IPF),,Yes,,"Adult , Elderly","Female , Male"
12502,2020-001429-30,WA42294,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF),Not Commenced,,21/12/2020,09/04/2021,A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Patients with Idiopathic Pulmonary Fibrosis,No,Idiopathic pulmonary fibrosis (IPF),,Yes,,"Adult , Elderly","Female , Male"
12522,2020-003510-12,GS-US-540-9012,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734¿) Treatment of COVID-19 in an Outpatient Setting",Ended,,22/12/2020,16/02/2021,A study to test a drug named remdesivir to evaluate the efficacy and safety of the drug in treating patients with COVID-19 in an outpatient setting (non-hospitalized),No,COVID-19,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
12542,2020-003117-35,EFC16723,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP)",Not Commenced,,29/03/2021,07/05/2021,Dupilumab in CRSsNP,No,Chronic rhinosinusitis without nasal polyposis ,Yes,Yes,,Under 18,"Female , Male"
12562,2019-003616-31,MK-7339-013,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)",Not Commenced,,09/07/2021,30/04/2021,"A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)",No,Limited-Stage Small Cell Lung Cancer (LS-SCLC),,Yes,,"Adult , Elderly","Female , Male"
12582,2020-002536-67,ISIS678354-CS3,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA¿APOCIII¿LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)",Not Commenced,,11/03/2021,09/04/2021,A Study of AKCEA-APOCIIILRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS),No,Familial Chylomicronemia Syndrome (FCS),,Yes,,"Adult , Elderly","Female , Male"
12602,2018-004004-19,QBGJ398-301,Interventional studies with investigational medicinal products,"QED Therapeutics, Inc.","A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial",Active,,13/04/2021,05/02/2021,"A study to determine whether infigratinib improves the treatment for cholangiocarcinoma compared with the standard of care, chemotherapy gemcitabine with cisplatin, for patients with a genetic abnormality in the Fibroblast Growth Factor Receptor 2 (FGFR2) gene.  ",No,Cholangiocarcinoma,,Yes,,"Adult , Elderly","Female , Male"
12642,2020-001969-37,19386A,Interventional studies with investigational medicinal products,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache",Active,,02/06/2021,31/05/2021,A study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headache,No,Episodic cluster headache,,Yes,,"Adult , Elderly","Female , Male"
12662,2020-002951-39,CAAA601A32201,Interventional studies with investigational medicinal products,Advanced Accelerator Applications SA,"A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas",Not Commenced,,14/06/2021,30/09/2021,"Phase 2 study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs, pheochromocytoma and paragangliomas",No,"somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas",Yes,,,Under 18,"Female , Male"
12682,2020-001176-15,BIA-91067-405,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson¿s disease patients with end-of-dose motor fluctuations and associated sleep disorders.",Active,,29/01/2021,19/03/2021,Clinical study to investigate if Opicapone 50mg can reduce sleep disorders associated to Parkinson's disease.,No,Parkinson's disease patients with wearing-off motor fluctuations and associated sleep disorders.,,,Yes,"Adult , Elderly","Female , Male"
12702,2019-004594-44,NN9931-4553,Interventional studies with investigational medicinal products,Novo Nordisk A/S,The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis,Active,,17/03/2021,09/09/2021,Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH),No,Non-alcoholic steatohepatitis,,Yes,,"Adult , Elderly","Female , Male"
12722,2020-002333-15,20739,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy ",Active,,22/03/2021,19/03/2021,Non-proliferative diabetic retinopathy treated with runcaciguat,No,"- Non-proliferative diabetic retinopathy: early stage of a medical condition in which damage occurs to the retina due to diabetes mellitus (DM)
- DM is characterized by too much sugar in the blood",Yes,,,"Adult , Elderly","Female , Male"
12742,2020-003106-31,MK3475-B15,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Phase 3, Randomized, Open-label Study to Evaluate Perioperative
Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer
(KEYNOTE-B15 / EV-304)",Not Commenced,,29/04/2021,12/07/2021,Ph3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC,No,Urothelial Carcinoma and Muscle Invasive Bladder Cancer,,Yes,,"Adult , Elderly","Female , Male"
12762,2019-004511-31,cASPerCF_2007_OPBG_2019,Interventional studies with investigational medicinal products, IRCCS Ospedale Pediatrico Bambino Gesù (OPBG),Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.,Not Commenced,,14/06/2021,18/06/2021,"Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.
",No,Cystic Fibrosis and Aspergillus infection.,Yes,Yes,,Under 18,"Female , Male"
12782,2020-003507-34,APD334-210,Interventional studies with investigational medicinal products,"Arena Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis",Active,,08/01/2021,26/02/2021,Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis,No,Ulcerative Colitis,Yes,,,"Adult , Elderly","Female , Male"
12822,2019-004838-41,CSOK583A12301,Interventional studies with investigational medicinal products,Hexal AG,"A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration",,,01/07/2021,30/04/2021,"The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator",No,"The `wet¿ form of age-related macular degeneration (AMD) is a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling (Eylea SmPC)",,Yes,,"Adult , Elderly","Female , Male"
12842,2020-001314-37,BUL-8/EEA,Interventional studies with investigational medicinal products,Dr. Falk Pharma GmbH                                                                                ,"Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis",Active,,18/06/2021,26/11/2021,Clinical study to show equal clinical efficacy of two dosing regimen of budesonid orodispersible tablets (twice daily vs. once daily) for treatment of inflammation of the esophagus,No,eosinophilic esophagitis,,Yes,,"Adult , Elderly","Female , Male"
12882,2020-003982-20,DS8201-A-U305,Interventional studies with investigational medicinal products,"Daiichi Sankyo, Inc.","A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy",Not Commenced,,17/09/2021,21/05/2021,Clinical  trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer following neoadjuvant therapy,No,High-Risk HER2-Positive Breast Cancer ,,Yes,,"Adult , Elderly","Female , Male"
12902,2020-002723-11,1404-0043,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis",Active,,26/04/2021,21/05/2021,A study to test whether different doses of BI 456906 are effective in people with a liver disease called non-alcoholic steatohepatitis (NASH) and liver fibrosis,No,non-alcoholic steatohepatitis,Yes,,,"Adult , Elderly","Female , Male"
12922,2020-003288-24,GRN163LMYF3001,Interventional studies with investigational medicinal products,Geron Corporation,"A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor",Not Commenced,,25/05/2021,30/04/2021,A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to JAK-inhibitor treatment,No,Myelofibrosis,,Yes,,"Adult , Elderly","Female , Male"
12962,2020-003990-23,BP42698,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING
STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS",Not Commenced,,16/06/2021,18/06/2021,A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis,No,Autoimmune Hepatitis (AIH),Yes,,,"Adult , Elderly","Female , Male"
12963,2020-002929-28,1366-0005,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease",Active,,10/05/2021,15/10/2021,A study to test the effect of different doses of BI 685509 on kidney function in people with diabetic kidney disease,No,diabetic kidney disease,Yes,,,"Adult , Elderly","Female , Male"
12964,2020-002930-33,1366-0022,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with non-diabetic kidney disease.",Active,,10/05/2021,15/10/2021,"A study to test the effect of different doses of BI 685509 on kidney
function in people with chronic kidney disease",No,non-diabetic kidney disease,Yes,,,"Adult , Elderly","Female , Male"
12982,2020-001819-24,EFC16819,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)",Not Commenced,,05/04/2021,10/05/2021,"Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-2)",No,Chronic Obstructive Pulmonary Disease,,Yes,,"Adult , Elderly","Female , Male"
12983,2020-001048-24,NN7769-4514,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.",Not Commenced,,26/05/2021,18/03/2022,A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitors,Yes,"Haemophilia A 
Haemophilia A with inhibitors",,Yes,,"Under 18 , Adult , Elderly","Female , Male"
13002,2020-004743-83,SG018,Interventional studies with investigational medicinal products,Synairgen Research Ltd,"A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19",Active,,17/03/2021,13/04/2021,A trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients hospitalised with moderate COVID-19,No,COVID-19,,Yes,,"Adult , Elderly","Female , Male"
13022,2017-004886-29,MN39158,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN
PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL",Active,,25/05/2021,21/05/2021,A  Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial,No,Multiple sclerosis (MS),,Yes,,Adult,"Female , Male"
13042,2020-004032-21,ARGX-113-2004,Interventional studies with investigational medicinal products,Argenx BV,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",Active,,19/07/2021,18/06/2021,A Phase 3 study to evaluate the efficacy and safety of efgartigimod PH 20 Subcutaneous in adult patients with primary immune thrombocytopenia.,No,Primary immune thrombocytopenia (ITP),,Yes,,"Adult , Elderly","Female , Male"
13102,2020-004523-16,GR42691,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION
STUDY TO EVALUATE THE LONG-TERM SAFETY
AND TOLERABILITY OF FARICIMAB IN PATIENTS
WITH NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION",Active,,12/03/2021,04/09/2021,A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration,No,Neovascular age-related macular degeneration (nAMD),,Yes,,"Adult , Elderly","Female , Male"
13122,2020-005416-22,GS-US-540-5912,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19",Active,,11/03/2021,07/04/2021,A Phase 3 Study of Remdesivir in Participants with Severe Renal Impairment who are in Hospital for COVID-19,No,Coronavirus disease 2019 (COVID-19) in patients with chronic renal impairment,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
13162,2020-003655-15,CA209-67T,Interventional studies with investigational medicinal products,Bristol-Myers Squibb International Corporation,"A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy.",Ended,,29/07/2021,23/07/2021,A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma,No,Metastatic Clear Cell Renal Cell Carcinoma,,Yes,,"Adult , Elderly","Female , Male"
13182,2020-001400-41,BNT113-01,Interventional studies with investigational medicinal products,BioNTech SE,"An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1.",Not Commenced,,31/01/2022,07/09/2021,"A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1",No,"Unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1",Yes,,,"Adult , Elderly","Female , Male"
13202,2020-004287-26,5F9009,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome",Active,,07/04/2021,23/07/2021,A study comparing efficacy of Magrolimab in combination with Azacitidine versus Azacitidine Plus Placebo in previously untreated patients with higher risk Myelodysplastic Syndrome,No,Intermediate/high/very high risk myelodysplastic syndrome (MDS) ,,Yes,,"Adult , Elderly","Female , Male"
13222,2020-005011-52,BIA-91067-303,Interventional studies with investigational medicinal products,"Bial - Portela & Cª, S.A.                                                                           ","A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson¿s Disease Patients, with an Open-Label Extension
The EPSILON Study: Early Parkinson wIth L-DOPA/DDCI and Opicapone
",Not Commenced,,21/05/2021,03/09/2021,"Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopathic Parkinson¿s Disease Patients: The EPSILON Study",No,Early Idiopathic Parkinson¿s disease ,,Yes,,"Adult , Elderly","Female , Male"
13302,2020-002276-12,D8532C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease",Active,,14/04/2021,02/07/2021,"A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease",No,"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",,Yes,,"Adult , Elderly","Female , Male"
13322,2020-004336-16,CC-93538-EE-001,Interventional studies with investigational medicinal products,Celgene International II Sàrl,"A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis
",Active,,27/08/2021,24/09/2021,A study to evaluate the efficacy and safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitis,No,EOSINOPHILIC ESOPHAGITIS,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
13342,2020-004553-72,LOXO-BTK-20019,Interventional studies with investigational medicinal products,"Loxo Oncology, Inc.","A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)",Active,,18/05/2021,13/08/2021,A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in patients with previously treated Mantle Cell Lymphoma,No,Mantle cell lymphoma,,Yes,,"Adult , Elderly","Female , Male"
13362,2014-001633-84,20140106,Interventional studies with investigational medicinal products,"Onyx Therapeutics, Inc., an Amgen Inc. subsidiary",Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia,Not Commenced,,06/09/2021,14/07/2021,Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia,Yes,Relapsed or Refractory Acute Lymphoblastic Leukemia,Yes,,,"Under 18 , Adult","Female , Male"
13422,2019-004682-40,CBYL719K12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.",Active,,06/09/2021,18/06/2021,Study to assess the efficacy and safety of alpelisib in combination with olaparib in patients with high-grade serous ovarian cancer without hereditary BRCA mutation that did not respond to prior platinum-based chemotherapy or recurred within six months after such therapy.,No,"Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation",,Yes,,"Adult , Elderly",Female
13442,2020-003617-36,D-PLEX312,Interventional studies with investigational medicinal products,PolyPid Ltd.,"Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.",Not Commenced,,22/06/2021,23/07/2021,Study of D-PLEX in prevention of infections following abdominal surgeries.,No,Prevention of post abdominal surgery incisional infection.,,Yes,,"Adult , Elderly","Female , Male"
13462,2021-000946-16,TryptoBPH,Interventional studies with investigational medicinal products,"Centro Clínico Académico - Braga, Associação (2CA-Braga)",TryptoBPH - Proof-of-concept study to evaluate the safety and efficacy of tryptophan in patients with BPH,Not Commenced,,15/11/2021,17/12/2021,TryptoBPH - a study to evaluate the safety and efficacy of tryptophan in patients with Benign Prostate Hyperplasia,No,Benign Prostate Hyperplasia,Yes,,,"Adult , Elderly",Male
13482,2020-003313-35,DCR-A1AT-201,Interventional studies with investigational medicinal products,"Dicerna Pharmaceuticals, Inc.","A Phase 2a, Randomized, Double-blind, Placebo controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Belcesiran in Patients with PiZZ Alpha-1 Antitrypsin Deficiency",,,02/08/2021,09/08/2021,"A clinical study to evaluate safety, tolerability, Pharmacokinetics and Pharmacodynamis of Belcesiran in patients with PiZZ Alpha-1 Antitrypsin Deficiency. ",No,PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease,Yes,,,"Adult , Elderly","Female , Male"
13502,2020-002964-29,IMMU-132-13,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.",A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician¿s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer,Active,,04/08/2021,02/07/2021,"A study to compare study medication Sacituzumab Govitecan with Standard
of Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapy",No,Metastatic or Locally Advanced Unresectable Urothelial Cancer,,Yes,,"Adult , Elderly","Female , Male"
13522,2019-000569-19,MK-7902-009,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)",Not Commenced,,27/09/2021,02/07/2021,A Phase 2 study of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that has progressed after platinum therapy and immunotherapy (LEAP-009),No,Recurrent/metastatic head and neck squamous cell carcinoma,Yes,,,"Adult , Elderly","Female , Male"
13542,2020-000431-49,CC-220-MM-002,Interventional studies with investigational medicinal products,Celgene Corporation,"A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)",Not Commenced,,15/09/2021,06/07/2021,"A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, and Dexamethasone in patients with a non-responsive or progressive blood cancer called Multiple Myeloma",No,Relapsed or Refractory Multiple Myeloma (RRMM),,Yes,,"Adult , Elderly","Female , Male"
13562,2020-005588-29,1487-0001,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group,
group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the
treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19.",Not Commenced,,27/04/2021,19/04/2021,A study to test BI 767551 in people with mild to moderate symptoms of COVID-19.,No,COVID-19,Yes,Yes,,"Adult , Elderly","Female , Male"
13702,2020-003645-11,849-012,Interventional studies with investigational medicinal products,"Mirati Therapeutics, Inc.",A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Not Commenced,,27/09/2021,17/09/2021,Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,No,Advanced Non-Small Cell Lung Cancer,,Yes,,"Adult , Elderly","Female , Male"
13722,2020-002700-39,CBAF312D2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021",Active,,19/07/2021,02/11/2021,Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis.,Yes,Multiple Sclerosis in pediatric patients,,Yes,,Under 18,"Female , Male"
13742,2020-005759-18,CV43043,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 AT-527 IN PATIENTS WITH MILD OR MODERATE COVID-19",Active,,25/05/2021,27/05/2021,"A study to evaluate the Efficacy, Safety, and Antiviral Activity of RO7496998 (AT-527) in Patients with Mild or Moderate COVID-19",No,Mild to Moderate coronavirus disease 2019 (COVID-19),,Yes,,"Adult , Elderly","Female , Male"
13783,2020-004040-29,CY5031,Interventional studies with investigational medicinal products,"Cytokinetics, Inc.","A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). ",Not Commenced,,16/08/2021,14/01/2022,A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested.,No,Amyotrophic Lateral Sclerosis (ALS),,Yes,,"Adult , Elderly","Female , Male"
13802,2020-004848-29,NN6535-4730,Interventional studies with investigational medicinal products,Novo Nordisk A/S,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer¿s disease (EVOKE),Active,,05/07/2021,24/09/2021,A research study investigating semaglutide in people with early Alzheimer¿s disease (EVOKE),No,"Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer¿s type",,Yes,,"Adult , Elderly","Female , Male"
13822,2020-004864-25,NN6535-4725,Interventional studies with investigational medicinal products,Novo Nordisk A/S,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer¿s disease (EVOKE plus),Active,,05/07/2021,24/09/2021,A research study investigating semaglutide in people with early Alzheimer¿s disease (EVOKE plus),No,"Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer¿s type",,Yes,,"Adult , Elderly","Female , Male"
13882,2020-004559-34,DS8201-A-U306,Interventional studies with investigational medicinal products,"Daiichi Sankyo, Inc.","A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)",Not Commenced,,22/10/2021,12/10/2021,Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or After a Trastuzumab-Containing Regimen,No,HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ)Adenocarcinoma,,Yes,,"Adult , Elderly","Female , Male"
13902,2021-000129-28,GO42784,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER.",Active,,06/07/2021,11/10/2021,"A study to evaluate the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.",No,"Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. ",,Yes,,"Adult , Elderly","Female , Male"
13922,2021-000037-14,NEOD001-301,Interventional studies with investigational medicinal products,Prothena Biosciences Limited,"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis",Active,,10/09/2021,03/09/2021,"A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis",No,"AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia",,Yes,,"Adult , Elderly","Female , Male"
13942,2020-005407-38,MK-3475-B49,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)",Not Commenced,,01/09/2021,13/08/2021,"This trial is testing pembrolizumab (pembro) + chemotherapy (chemo) in people with certain types of breast cancer called hormone receptor positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced inoperable or metastatic breast cancer (MBC).

",No,Treatment of patients with HR+/HER2- locally recurrent inoperable or MBC whose tumors express PD-L1,,Yes,,"Adult , Elderly","Female , Male"
13962,2021-000627-12,CV43140,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY",Active,,15/06/2021,13/08/2021,"A Six-Month Follow-Up Study of Patients with COVID-19 Previously Enrolled in a RO7496998 (AT-527) Study

",No,Coronavirus disease 2019 (COVID-19),,Yes,,"Under 18 , Adult","Female , Male"
13982,2021-000541-41,N/A,Interventional studies with investigational medicinal products,Oslo University Hospital,European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial,Not Commenced,,22/06/2021,13/08/2021,Joint European Research on active and emerging pandemics,No,SARS-CoV infection,,Yes,,"Adult , Elderly","Female , Male"
14042,2020-005995-37,COAV101A12306,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A Phase lllb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA)",Ended,,11/08/2021,15/10/2021,Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART),No,Spinal Muscular Atrophy,,Yes,,Under 18,"Female , Male"
14062,2020-001648-24,MedOPP321,Interventional studies with investigational medicinal products,MedSIR (Medica Scientia Innovation Research),"A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria. (ABIGAIL)",Active,,15/11/2021,26/11/2021,A study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of chemotherapy with paclitaxel in patients with unresectable locally advanced or metastatic  breast cancer with aggressive disease criteria.,No,Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease criteria.,Yes,,,"Adult , Elderly","Female , Male"
14102,2020-004775-40,APD334-202EU,Interventional studies with investigational medicinal products,"Arena Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn¿s Disease",Not Commenced,,16/06/2021,24/09/2021,A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's Disease,No,Crohn's Disease,Yes,Yes,,"Adult , Elderly","Female , Male"
14122,2020-002141-42,NL73593,Interventional studies with investigational medicinal products,Catharina Hospital ,"Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer - PelvEx II study",,,12/04/2022,15/10/2021,Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study,No,Locally recurrent rectal cancer,,Yes,,"Adult , Elderly","Female , Male"
14142,2021-000016-28,212483,Interventional studies with investigational medicinal products,ViiV Healthcare UK Limited,"A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatment-naïve adults",Not Commenced,,06/09/2021,26/11/2021,A Phase IIb Clinical Trial of GSK3640254 + Dolutegravir (DTG) in HIV-1 Infected Treatment-Naive Adults ,No,Human Immunodeficiency Virus Type-1 (HIV-1),Yes,,,"Adult , Elderly","Female , Male"
14162,2020-005452-38,D910PC00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer 
(VOLGA)",Not Commenced,,25/03/2022,20/05/2022,"Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin",No,Documented muscle-invasive urothelial carcinoma (UC) of the bladder in cisplatin ineligible patients or Who Refuse Cisplatin,,Yes,,"Adult , Elderly","Female , Male"
14202,2020-004048-27,849-010,Interventional studies with investigational medicinal products,"Mirati Therapeutics, Inc.",A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy,Not Commenced,,02/12/2021,26/11/2021,Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation,No,Advanced Colorectal Cancer with KRAS G12C Mutation ,,Yes,,"Adult , Elderly","Female , Male"
14262,2020-005048-46,D9673C00007,Interventional studies with investigational medicinal products,AstraZeneca AB,"An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic
HER2-Positive Breast Cancer (DESTINY-Breast12)",Active,,24/09/2021,15/10/2021,A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Treated Advanced or Metastatic HER2 Positive Breast Cancer,No,Treatment of patients with HER2-positive breast cancer with or without brain metastasis,,Yes,Yes,"Adult , Elderly","Female , Male"
14382,2021-000465-32,CNTO1959PSA4002,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease ",Active,,30/11/2021,17/03/2022,Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants ,No,Active Psoriatic Arthritis Axial Disease,,,Yes,"Adult , Elderly","Female , Male"
14442,2020-004853-59,EX6018-4758,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation",Active,,15/02/2022,26/11/2021,"ZEUS ¿ A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation",Yes,"Atherosclerotic cardiovascular disease
Chronic kidney disease 
Systemic inflammation",,Yes,,"Adult , Elderly","Female , Male"
14462,2019-002549-39,Ponatinib-1501,Interventional studies with investigational medicinal products,"Takeda Development Center Americas, Inc.","A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of   Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation",Active,,21/10/2021,14/01/2022,"Ponatinib With Chemotherapy in Pediatric Patients With Relapsed, Resistant, or Intolerant Ph+ ALL or Have the T315I Mutation",Yes,acute lymphoblastic leukemia,Yes,,,"Under 18 , Adult","Female , Male"
14482,2020-005951-19,APL-D-003-20,Interventional studies with investigational medicinal products,"PharmaMar, S.A.","A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management of Moderate COVID-19 Infection",Not Commenced,,30/07/2021,29/11/2021,This study is for research purposes only to test plitidepsin for patients requiring hospitalization due to COVID-19.,No,moderate COVID-19 infection,,Yes,,"Adult , Elderly","Female , Male"
14502,2021-000829-27,LPS16747,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients

",Not Commenced,,03/08/2021,26/11/2021,EVEREST: EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients,No,Chronic rhinosinusitis with nasal polyps,,,Yes,"Adult , Elderly","Female , Male"
14582,2021-001242-35,68284528MMY3004,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",Not Commenced,,07/06/2022,24/11/2021,"A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy",No,Multiple Myeloma,,Yes,,"Adult , Elderly","Female , Male"
14602,2020-005173-28,BLU-263-1201,Interventional studies with investigational medicinal products,Blueprint Medicines Corporation,"A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis",Not Commenced,,30/11/2021,06/01/2022,A Study of BLU-263 in patients with Indolent Systemic Mastocytosis,No,Indolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS),Yes,Yes,,"Under 18 , Adult , Elderly","Female , Male"
14622,2020-004128-41,WN42086,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS",Not Commenced,,27/12/2021,17/11/2022,A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis,Yes,Relapsing-Remitting Multiple Sclerosis,,Yes,,Under 18,"Female , Male"
14642,2020-000362-42,THR-687-002,Interventional studies with investigational medicinal products,Oxurion NV,"A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular oedema (DME)",Not Commenced,,10/12/2021,14/01/2022,A study to evaluate THR-687 treatment for diabetic macular oedema,No,Diabetic macular oedema (DME) ,Yes,,,"Adult , Elderly","Female , Male"
14682,2021-000665-32,80202135SJS2001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS)",Active,,09/11/2021,05/11/2021,A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS),No,Primary Sjogren's Syndrome,Yes,,,"Adult , Elderly","Female , Male"
14702,2020-000315-76,1375_RCF_MAC,Interventional studies with investigational medicinal products,"Centro Hospitalar Universitário Lisboa Central, EPE",Low molecular weight heparin in the treatment of early fetal growth restriction,Not Commenced,,06/12/2021,26/11/2021,Heparin in the treatment of fetal growth restriction,No,Early fetal growth restriction,Yes,,,Adult,Female
14722,2020-004891-16,CL3-05179-002,Interventional studies with investigational medicinal products,"SERVIER PORTUGAL - ESPECIALIDADES FARMACÊUTICAS, LDA.","Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combination of perindopril 10 mg, indapamide 2.5 mg and amlodipine 5 or 10 mg in patients with uncontrolled essential hypertension. An international, multicentre, randomised, double-blind, 16-week study.",Active,,04/02/2022,23/03/2022,"A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,
indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.",No,Hypertension,,Yes,,"Adult , Elderly","Female , Male"
14742,2020-004184-12,DTX401-CL301,Interventional studies with investigational medicinal products,Ultragenyx Pharmaceutical Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.

EMA Decision number on PIP: EMA/PDCO/154270/2021
",Active,,17/03/2022,08/02/2022,An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Disease Type Ia.,Yes,Glycogen Storage Disease Type Ia (GSDIa).,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
14762,2021-000296-36,ZWI-ZW25-301,Interventional studies with investigational medicinal products,Zymeworks Inc.,"A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)",Active,,31/08/2021,17/12/2021,A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers,No,Gastroesophageal Adenocarcinoma (GEA),,Yes,,"Adult , Elderly","Female , Male"
14802,2020-005770-99,1368-0059,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn¿s Disease",Not Commenced,,17/12/2021,05/11/2021,A study to test whether spesolimab helps people with Crohn¿s disease who have symptoms of bowel obstruction,No,Fibrostenotic Crohn¿s Disease,Yes,,,"Adult , Elderly","Female , Male"
14842,2021-000199-12,A011-13,Interventional studies with investigational medicinal products,Acceleron Pharma Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension
(PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients.",Not Commenced,,24/01/2022,18/02/2022,A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary arterial hypertension (PAH) Patients.,No,Pulmonary Arterial Hypertension (PAH),,Yes,,Adult,"Female , Male"
14862,2021-000050-26,AV-951-20-304,Interventional studies with investigational medicinal products,"AVEO Pharmaceuticals, Inc.","TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
",Not Commenced,,09/02/2022,18/03/2022,Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma ,No,Renal Cell Carcinoma ,,Yes,,"Adult , Elderly","Female , Male"
14882,2020-001521-31,D5982C00008,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma",Not Commenced,,09/02/2022,03/05/2022,A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with Severe Asthma Inadequately Controlled with Standard of Care.,Yes,Severe and inadequately controlled asthma,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
14942,2020-005764-62,HZNP-HZN-825-301,Interventional studies with investigational medicinal products,Horizon Therapeutics Ireland DAC,"A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis",Not Commenced,,20/08/2021,24/08/2021,"A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis",No,Diffuse Cutaneous Systemic Sclerosis,Yes,,,"Adult , Elderly","Female , Male"
15022,2018-001671-21,KRT-232-101,Interventional studies with investigational medicinal products,"Kartos Therapeutics, Inc.","A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232  in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment ",Active,,18/02/2022,04/02/2022,"This global, multicenter, Phase 2 (Part A)/3 (Part B) randomized, controlled, open-label study will evaluate the safety and efficacy of KRT-232 versus BAT for the treatment PMF, post PV MF, or post ET MF in subjects who are relapsed or refractory to JAK inhibitor treatment",No,Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) With Intermediate Or High-Risk TP53 Wild-Type (TP53 WT) Who Are Relapsed Or Refractory to Janus Kinase (JAK) - Inhibitor Treatment.,Yes,Yes,,"Adult , Elderly","Female , Male"
15042,2021-002006-27,CKJX839B12302,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)",Active,,22/12/2021,26/11/2021,"A research study  to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people who already have vascular disease.",No,Atherosclerotic cardiovascular disease (ASCVD),,Yes,,"Adult , Elderly","Female , Male"
15082,2019-003777-26,D0817C00098,Interventional studies with investigational medicinal products,AstraZeneca AB,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,Not Commenced,,08/09/2021,03/01/2022,Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib,No,"BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrial cancer
",,Yes,,"Adult , Elderly",Female
15142,2020-004855-34,21652,Interventional studies with investigational medicinal products,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women",Active,,27/01/2022,17/12/2021,A study to learn more about how well elinzanetant works and how safe it is for the treatment of vasomotor symptoms (hot flashes) that are caused by hormonal changes over 26 weeks in women who have been through the menopause,No,Vasomotor symptoms associated with menopause,,Yes,,"Adult , Elderly",Female
15162,2021-002549-13,CSUC-01/21,Interventional studies with investigational medicinal products,InDex Pharmaceuticals AB,"A Randomised Double-Blind Placebo-Controlled Phase III Clinical 
Study to Evaluate the Efficacy and Safety of Cobitolimod as an 
Induction and Maintenance Therapy in Participants with Moderate 
to Severe Active Left-Sided Ulcerative Colitis
",,,02/08/2022,23/02/2022,A Phase III Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Severe Active Left-Sided Ulcerative Colitis,No,Moderate to Severe left-sided Active Ulcerative Colitis,,Yes,,"Adult , Elderly","Female , Male"
15182,2020-004986-38,337HNAS20011,Interventional studies with investigational medicinal products,INVENTIVA SA,"A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis 
",Not Commenced,,24/11/2021,18/03/2022,"A clinical study to assess the long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis 
",No,Non-alcoholic Steatohepatitis (NASH),,Yes,,"Adult , Elderly","Female , Male"
15202,2021-001825-33,61186372NSC3002,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",Not Commenced,,12/04/2022,03/03/2022,A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure,No,Locally Advanced or Metastatic Non-Small Cell Lung Cancer ,,Yes,,"Adult , Elderly","Female , Male"
15222,2020-005708-20,GS-US-548-5916,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.",A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma,Active,,22/02/2022,18/03/2022,A study evaluating safety and efficacy of magrolimab in combination with chemotherapy for the treatment of Head and Neck Squamous Cell Carcinoma.,No,Head and Neck Squamous Cell Carcinoma,Yes,,,"Adult , Elderly","Female , Male"
15282,2021-002566-40,20200491,Interventional studies with investigational medicinal products,Amgen Inc.,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment",Active,,10/11/2021,14/01/2022,A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC),No,Relapsed/Refractory Small Cell Lung Cancer,Yes,,,"Adult , Elderly","Female , Male"
15302,2021-000352-19,MOG001,Interventional studies with investigational medicinal products,UCB Biopharma SRL,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin
Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)",,,14/09/2022,21/02/2022,A study to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD),No,Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD),,Yes,,"Adult , Elderly","Female , Male"
15322,2021-003791-13,BP42992,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q SYNDROME.",Not Commenced,,15/02/2022,25/02/2022,"A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of 52 weeks of Treatment with Basmisanil in Children with Dup15q Syndrome.",No,Dup15q Syndrome,Yes,,,Under 18,"Female , Male"
15342,2021-000712-31,VX20-121-102,Interventional studies with investigational medicinal products,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
",Not Commenced,,03/01/2022,07/03/2022,"A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation (F/MF)
",No,Cystic Fibrosis,,Yes,,"Under 18 , Adult","Female , Male"
15402,2021-002461-18,20-214-36,Interventional studies with investigational medicinal products,Nektar Therapeutics,"A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)",Not Commenced,,15/02/2022,21/02/2022,Bempegaldesleukin with pembrolizumab in patients with PD-L1 (programmed cell death-ligand 1) positive Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma (HNSCC).,No,Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors,Yes,Yes,,"Adult , Elderly","Female , Male"
15422,2021-000474-29,PTC923-MD-003-PKU,Interventional studies with investigational medicinal products,"PTC Therapeutics, Inc.",A Phase 3 Study of PTC923 in Subjects with Phenylketonuria,Not Commenced,,02/02/2022,04/02/2022,A Phase 3 Study of PTC923 in Subjects with Phenylketonuria,No,Metabolic Disorders - Phenylketonuria,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
15462,2021-001966-39,CBYL719C2303,Interventional studies with investigational medicinal products,Novartis Pharma AG,"EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor",Active,,21/10/2021,15/10/2021,"A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cancer after treatment with a CDK4/6 inhibitor and an aromatase inhibitor",No,"Hormone receptor positive, HER2-negative advanced breast cancer",,Yes,,"Adult , Elderly","Female , Male"
15502,2021-001234-20,LOXO-BTK-20023,Interventional studies with investigational medicinal products,"Loxo Oncology, Inc.","A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)",Not Commenced,,20/01/2022,01/04/2022,A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL,No,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,,Yes,,"Adult , Elderly","Female , Male"
15522,2020-004335-24,CC-93538-EE-002,Interventional studies with investigational medicinal products,Celgene International II Sàrl,"A  PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
",Active,,24/02/2022,17/01/2022,A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitis,No,EOSINOPHILIC ESOPHAGITIS,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
15582,2021-001928-17,GCT1046-04,Interventional studies with investigational medicinal products,Genmab A/S,"A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor",,,17/10/2022,15/07/2022,"A Safety and Efficacy Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Recurrent Non-Small Cell Lung 
 cancer",No,Malignant Solid Tumors - Non Small Cell Lung Cancer,Yes,,,"Adult , Elderly","Female , Male"
15622,2020-005061-13,A011-12,Interventional studies with investigational medicinal products,Acceleron Pharma Inc.,An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH,Active,,09/03/2022,18/03/2022,A Long-term Follow-up Study of Sotatercept for PAH Treatment,No,Pulmonary Arterial Hypertension (PAH),,Yes,,"Adult , Elderly","Female , Male"
15702,2021-001427-40,ION-682884-CS13,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc","An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",Not Commenced,,07/06/2022,18/02/2022,Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy,No,Hereditary Transthyretin-Mediated Amyloid Polyneuropathy,,Yes,,"Adult , Elderly","Female , Male"
15722,2021-003578-30,GS-US-577-6153,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",Not Commenced,,30/06/2022,18/03/2022,A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),No,Non-Small Cell Lung Cancer,,Yes,,"Adult , Elderly","Female , Male"
15742,2020-005929-89,CLOU064C12302,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib",Not Commenced,,01/08/2022,12/04/2022,"Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib",No,Multiple Sclerosis,,Yes,,Adult,"Female , Male"
15762,2020-003384-25,DTX301-CL301,Interventional studies with investigational medicinal products,Ultragenyx Pharmaceutical Inc.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-Onset OTC Deficiency",,,10/03/2023,03/05/2022,A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients older than 12 years old with late-onset OTC deficiency,No,Late-onset Ornithine transcarbamylase (OTC) deficiency,,Yes,,"Under 18 , Adult","Female , Male"
15782,2019-004493-26,D9670C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator¿s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)",Not Commenced,,27/07/2022,03/06/2022,"Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator¿s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting",No,"HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.",,Yes,,"Adult , Elderly","Female , Male"
15802,2021-003226-71,MR42410,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE IIIB, MULTICENTER, RANDOMIZED,
VISUAL ASSESSOR-MASKED STUDY OF THE
EFFECTIVENESS AND SAFETY OF A 36-WEEK
REFILL REGIMEN FOR THE PORT DELIVERY
SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT
TREAT & EXTEND IN SUBJECTS WITH
NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION (DIAGRID)",Active,,17/05/2022,18/02/2022,A Study to Evaluate Effectiveness and Safety of A 36-Week Ranibizumab Refill Regimen for the Port Delivery System versus Aflibercept Intravitreal Injection Treat & Extend in Subjects with Neovascular Age-Related Macular Degeneration (DIAGRID),No,Age-related macular degeneration (AMD) is the leading cause of severe vision loss in individuals over the age of 50 years.,,Yes,,"Adult , Elderly","Female , Male"
15822,2021-003461-35,20210096,Interventional studies with investigational medicinal products,Amgen Inc.,"A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101)",Not Commenced,,07/07/2022,10/03/2022,Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression,No,Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression,,Yes,,"Adult , Elderly","Female , Male"
15842,2021-002071-19,19920,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria",Active,,26/04/2022,29/03/2022,"A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the body when taken by children with chronic kidney disease and proteinuria in addition to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker",Yes,"Chronic kidney disease
Proteinuria",,Yes,,Under 18,"Female , Male"
15862,2021-005320-38,VX21-445-124,Interventional studies with investigational medicinal products,Vertex Pharmaceuticals Incorporated,"A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation",Not Commenced,,17/03/2022,28/03/2022,Evaluation of Efficacy and Safety of ELX/TEZ/IVA in Subjects Without an F508del Mutation,No,Cystic Fibrosis,,Yes,,"Under 18 , Adult","Female , Male"
15882,2021-002491-39,SGNTUC-028,Interventional studies with investigational medicinal products,Seagen Inc.,"A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)",Not Commenced,,04/05/2022,20/05/2022,A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast cancer,No,Unresectable locally-advanced or metastatic HER2+ breast cancer,,Yes,,"Adult , Elderly","Female , Male"
15944,2020-005269-15,CO42865,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER",Not Commenced,,01/08/2022,05/07/2022,A Study of Pralsetinib versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer,Yes,RET-mutated Medullary Thyroid Cancer (MTC),,Yes,,"Under 18 , Adult , Elderly","Female , Male"
15962,2021-001924-16,FDY-5301-302,Interventional studies with investigational medicinal products,"Faraday Pharmaceuticals, Inc.","IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, 
Placebo-Controlled, Multicenter Study of Intravenous 
FDY-5301 in Patients with an Anterior ST-Elevation 
Myocardial Infarction",,,13/12/2022,03/05/2022,"A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) ",No,"Anterior ST-Elevation
Myocardial Infarction ",,Yes,,"Adult , Elderly","Female , Male"
16022,2020-003612-28,206785,Interventional studies with investigational medicinal products,GlaxoSmithKline Research & Development Limited,"A 52-week, randomised, double-blind, double-dummy, parallel group,multi-centre, non-inferiority study assessing exacerbation rate, 
additional measures  of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab",,,23/01/2023,08/04/2022,Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype,No,Severe asthma with  an eosinophilic phenotype ,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
16062,2021-004588-29,TA799-101,Interventional studies with investigational medicinal products,VectivBio AG,"A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy",Not Commenced,,12/04/2022,18/03/2022,Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host disease,No,Acute graft versus host disease (aGVHD),Yes,,,"Under 18 , Adult , Elderly","Female , Male"
16082,2020-003376-40,FAB122-CT-2001,Interventional studies with investigational medicinal products,Ferrer Internacional S.A,"A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis",Not Commenced,,24/06/2022,03/06/2022,"A study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
",No,Amyotrophic Lateral Sclerosis,,Yes,,"Adult , Elderly","Female , Male"
16102,2021-003149-39,C4181008,Interventional studies with investigational medicinal products,PFIZER INC,"A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",Not Commenced,,25/05/2022,29/04/2022,"Phase 2 study of long-term safety, tolerability, PK and efficacy of recifercept in achondroplasia",No,Achondroplasia,Yes,,,Under 18,"Female , Male"
16142,2020-002397-27,MK-2060-007,Interventional studies with investigational medicinal products,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis",Not Commenced,,07/06/2022,05/08/2022,A global trial to evaluate the efficacy and safety of MK-2060 in patients with end stage renal disease receiving hemodialysis,No,Prevention of arteriovenous graft thrombosis in patients with end stage renal disease receiving hemodialysis.,Yes,,,"Adult , Elderly","Female , Male"
16182,2021-000398-10,EFC16133,Interventional studies with investigational medicinal products,Sanofi-aventis recherche & développement,"A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-negative or positive, stage IIB-III breast cancer who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity",Not Commenced,,18/11/2022,05/08/2022,"Study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer, who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6)",No,Breast cancer,,Yes,,"Adult , Elderly","Female , Male"
16222,2020-001263-85,SAV006-05,Interventional studies with investigational medicinal products,Savara ApS,"A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP).",Not Commenced,,10/11/2022,29/04/2022,A clinical trial where patients with the lung disease autoimmune pulmonary alveolar proteinosis will be given the drug molgramostim nebulizer solution by inhalation.,No,Autoimmune Pulmonary Alveolar Proteinosis (aPAP),,Yes,,"Adult , Elderly","Female , Male"
16302,2021-001434-19,1378.5,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease",Active,,25/02/2022,04/01/2022,A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney disease,No,chronic kidney disease,Yes,,,"Adult , Elderly","Female , Male"
16402,2021-005184-42,CLEE011A2412B,Interventional studies with investigational medicinal products,Novartis Pharma AG,A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study,Not Commenced,,12/04/2022,08/04/2022,"Roll-over study to allow continued access to ribociclib
",No,"HR+, HER2- advanced or metastatic breast cancer",,,Yes,"Adult , Elderly","Female , Male"
16482,2021-002392-20,1403-0008,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",Active,,06/05/2022,17/06/2022,Brightline-1: A study to compare BI 907828 with doxorubicin in people with a type of cancer called dedifferentiated liposarcoma,No,advanced dedifferentiated liposarcoma,Yes,Yes,,"Adult , Elderly","Female , Male"
16562,2021-002555-10,DS1062-A-U304,Interventional studies with investigational medicinal products,"Daiichi Sankyo, Inc.","A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ¿50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)",Not Commenced,,20/09/2022,05/08/2022,Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations,No,Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),,Yes,,"Adult , Elderly","Female , Male"
16602,2020-003467-26,NN7769-4516,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 
(Mim8) prophylaxis in children with haemophilia A with or without FVIII 
inhibitors",Not Commenced,,07/07/2022,20/05/2022,A research study investigating Mim8 in children with haemophilia A with or without inhibitors,Yes,"Haemophilia A 

Haemophilia A with inhibitors",,Yes,,Under 18,"Female , Male"
16702,2021-001285-38,1366-0021,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis",Not Commenced,,17/06/2022,20/05/2022,A study to test whether two different doses of BI 685509 help people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver),No,portal hypertension ,Yes,,,"Adult , Elderly","Female , Male"
16723,2021-003536-92,CY6031,Interventional studies with investigational medicinal products,"CYTOKINETICS,Inc","A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction",Not Commenced,,14/12/2022,01/08/2022,A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertrophic cardiomyopathy (oHCM),No,obstructive hypertrophic cardiomyopathy (oHCM),,Yes,,"Adult , Elderly","Female , Male"
16802,2021-003222-76,ZX008-2103(EP0216),Interventional studies with investigational medicinal products,Zogenix International Limited,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABEL EXTENSION",Not Commenced,,19/09/2022,15/07/2022,A Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder,No,CDKL5 DEFICIENCY DISORDER,,Yes,,"Under 18 , Adult","Female , Male"
16822,2021-005746-15,MN43964,Interventional studies with investigational medicinal products,F. Hoffmann-La Roche Ltd,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",Not Commenced,,03/10/2022,22/06/2022,A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis,No,"Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerosis (RMS)",,Yes,,Adult,"Female , Male"
16842,2020-005281-34,NN1535-4591,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. COMBINE 1",Not Commenced,,07/10/2022,15/07/2022,"A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec (COMBINE 1)",No,"Diabetes Mellitus, Type 2",,Yes,,"Adult , Elderly","Female , Male"
16882,2019-002788-88,20190529,Interventional studies with investigational medicinal products,Amgen Inc.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)",Not Commenced,,09/08/2022,03/06/2022,Apremilast Study in Children with Active Juvenile Psoriatic Arthritis,Yes,Juvenile psoriatic arthritis,,Yes,,Under 18,"Female , Male"
16902,2020-003101-58,849-007,Interventional studies with investigational medicinal products,"Mirati Therapeutics, Inc.",A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation,Not Commenced,,27/09/2022,15/07/2022,Phase 2 Study of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation,No,Advanced Non-Small Cell Lung Cancer ,Yes,,,"Adult , Elderly","Female , Male"
16922,2021-003369-37,D9077C00001,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)",Not Commenced,,03/10/2022,16/09/2022,Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer,No,"Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer",Yes,,,"Adult , Elderly","Female , Male"
16962,2021-005607-13,NN8640-4467,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in
children with short stature either born small for gestational age or with Turner syndrome,
Noonan syndrome, or idiopathic short stature.",Not Commenced,,02/03/2023,26/08/2022,A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow,No,"Short stature born small for gestational age 
Turner syndrome
Noonan syndrome
Idiopathic short stature",,Yes,,Under 18,"Female , Male"
17022,2021-001910-13,AV-101-002,Interventional studies with investigational medicinal products,"Aerovate Therapeutics, Inc.","IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH).",Not Commenced,,26/08/2022,19/09/2022,"Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH.",No,Pulmonary Arterial Hypertension (PAH),Yes,Yes,,"Adult , Elderly","Female , Male"
17102,2021-005772-19,CAIN457Q12301E1,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis",Not Commenced,,03/10/2022,08/08/2022,"An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis",No,Lupus Nephritis,,Yes,,"Adult , Elderly","Female , Male"
17122,2021-003234-37,80202135CDP3001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",Not Commenced,,22/11/2022,08/08/2022,Efficacy and Safety Study of Nipocalimab for Adults with CIDP,No,Chronic Inflammatory Demyelinating Polyneuropathy,Yes,Yes,,"Adult , Elderly","Female , Male"
17142,2021-002046-33,CLNP023K12201,Interventional studies with investigational medicinal products,Novartis Pharma AG,"An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in patients with active lupus nephritis Class III-IV, +/- V",,,06/12/2022,05/08/2022,"Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V ",No,"Lupus Nephritis Class III-IV, +/- V",Yes,,,"Adult , Elderly","Female , Male"
17162,2021-003280-95,ISIS678354-CS13,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc",An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS),Not Commenced,,23/01/2023,15/07/2022,An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered to Patients with Familial Chylomicronemia Syndrome (FCS),No,Familial Chylomicronemia Syndrome (FCS),,Yes,,"Adult , Elderly","Female , Male"
17182,2021-000497-28,PTC923-MD-004-PKU,Interventional studies with investigational medicinal products,"PTC Therapeutics, Inc.",Phase 3 Open-Label Extension Study of PTC923 in Phenylketonuria,Not Commenced,,08/11/2022,03/06/2022,A Phase 3 Extension Study of PTC923 in Subjects with Phenylketonuria,No,Metabolic Disorders - Phenylketonuria,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
17202,2020-001009-22,19356A,Interventional studies with investigational medicinal products,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine",Not Commenced,,14/09/2022,08/09/2022,,Yes,Migraine ,,Yes,,Under 18,"Female , Male"
17222,2020-001649-38,19379A,Interventional studies with investigational medicinal products,H. Lundbeck A/S,"Long-term, open-label (dose-blinded), extension study of  eptinezumab in children and adolescents with chronic or episodic  migraine",Not Commenced,,22/09/2022,01/09/2022,,Yes,Migraine,,Yes,,Under 18,"Female , Male"
17242,2020-005661-14,CVAY736A2301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1) ",,,15/09/2022,03/06/2022,A clinical study to investigate if ianalumab is effective and safe in the treatment of active Sjögren`s syndrome,No,Active Sjögren's syndrome,,Yes,,"Adult , Elderly","Female , Male"
17282,2019-002637-11,CBYL719H12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.",Ended,,26/09/2022,24/06/2022,Study assessing the efficacy and safety of alpelisib plus nab-paclitaxel in subjects with advanced triple negative breast cancer  who carry either a PIK3CA  mutation or have PTEN loss without  PIK3CA mutation ,No,Advanced triple negative breast cancer,,Yes,,"Adult , Elderly","Female , Male"
17302,2021-002192-19,ISIS678354-CS5,Interventional studies with investigational medicinal products,"IONIS Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia",Not Commenced,,20/09/2022,26/08/2022,A Phase 3 study of investigational drug ISIS 678354 administered under skin to patients with severely increased amount of triglycerides in blood.  ,No,Severe hypertryglyceridemia,,Yes,,"Adult , Elderly","Female , Male"
17342,2018-003443-31,NUT-3/NAS,Interventional studies with investigational medicinal products,Dr. Falk Pharma GmbH                                                                                ,"Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)
",Not Commenced,,14/09/2022,15/07/2022,"Clinical trial comparing the efficacy and safety of norursodeoxycholic acid tablets with placebo in the treatment of non-alcholic fatty liver disease with liver inflammation (""non-alcoholic steatohepatitis""[NASH])",No,Non-alcoholic steatohepatitis (NASH) ,Yes,,,"Adult , Elderly","Female , Male"
17382,2021-005020-38,KF7039-02,Interventional studies with investigational medicinal products,Grünenthal GmbH                                                                                     ,"A randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of a single intra-articular injection of RTX-GRT7039 in adult subjects with pain associated with osteoarthritis of the knee.",,,03/10/2022,24/06/2022,Comparison of a single RTX-GRT7039 and placebo intra-articular injection for pain associated with osteoarthritis of the knee.,No,Moderate to severe pain associated with osteoarthritis of the knee,,Yes,,"Adult , Elderly","Female , Male"
17402,2021-002672-40,SGNTUC-029,Interventional studies with investigational medicinal products,Seagen Inc.,An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer,,,12/01/2023,14/09/2022,A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer,No,unresectable or metastatic HER2+ colorectal cancer,,Yes,,"Adult , Elderly","Female , Male"
17422,2021-000421-27,21177,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease",Not Commenced,,29/06/2022,03/06/2022,A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease,No,Non-diabetic chronic kidney disease,,Yes,,"Adult , Elderly","Female , Male"
17462,2021-000639-30,AB20009,Interventional studies with investigational medicinal products,AB Science,"A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse.",Not Commenced,,27/03/2023,20/09/2022,A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.,No,Patients with primary progressive or secondary progressive multiple sclerosis without relapse,,Yes,,Adult,"Female , Male"
17482,2021-005914-33,VX21-445-125,Interventional studies with investigational medicinal products,Vertex Pharmaceuticals Incorporated,A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes,Not Commenced,,01/08/2022,23/01/2023,Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del,No,Cystic Fibrosis,,Yes,,"Under 18 , Adult","Female , Male"
17502,2021-004450-36,MK-2140-006,Interventional studies with investigational medicinal products,Merck Sharp & Dohme LLC,"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (waveLINE-006).",Active,,22/12/2022,15/07/2022,A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malignancies,No,Aggressive and Indolent B-cell Malignancies,Yes,,,"Adult , Elderly","Female , Male"
17542,2021-003797-30,D9180C00003,Interventional studies with investigational medicinal products,AstraZeneca AB,"A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)",Not Commenced,,09/03/2023,03/02/2023,"Study to assess efficacy, safety, and tolerability of MEDI3506 in patients with symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations.",No,Chronic Obstructive Pulmonary Disease (COPD),,Yes,,"Adult , Elderly","Female , Male"
17562,2014-002471-28,TMC278IFD3004,Interventional studies with investigational medicinal products,Janssen Science Ireland UC,"An open-label, roll-over study with rilpivirine in combination with a background regimen containing other antiretrovirals (ARVs) in human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies",Not Commenced,,18/07/2022,08/08/2022,A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies,Yes,HIV-1 Infection,Yes,,,"Under 18 , Adult","Female , Male"
17602,2021-000491-10,CNTO1959CRD3005,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn¿s Disease

",,,29/03/2023,14/10/2022,"FUZION - Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn¿s Disease

",No,"Fistulizing perianal Crohn's Disease
",,Yes,,"Adult , Elderly","Female , Male"
17622,2021-002027-38,SOLTI-2101,Interventional studies with investigational medicinal products,SOLTI,"A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial",Not Commenced,,23/01/2023,16/09/2022,Comparative study of ribociclib and palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial,No,Patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer,,Yes,,"Adult , Elderly","Female , Male"
17642,2021-005726-15,217102,Interventional studies with investigational medicinal products,GlaxoSmithKline Research & Development Limited,"A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy",Not Commenced,,02/02/2023,02/09/2022,A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA),No,Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy,,Yes,,"Adult , Elderly","Female , Male"
17643,2021-004529-57,EQ-100-02,Interventional studies with investigational medicinal products,Equillium Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",Not Commenced,,21/09/2022,29/11/2022,A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication of Bone Marrow Transplants),No,Acute Graft Versus Host Disease,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
17662,2021-004979-14,AR-320-003,Interventional studies with investigational medicinal products,"Aridis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia",Not Commenced,,23/09/2022,13/01/2023,"A study to see if suvratoxumab is safe and works to stop pneumonia developing in people who are on mechanical ventilators who have a bacteria in their lungs, commonly called Staphylococcus, that has not yet caused an infection.",No,Prevention of nosocomial pneumonia,,Yes,,"Under 18 , Adult","Female , Male"
17682,2021-005879-40,U31402-A-U301,Interventional studies with investigational medicinal products,"Daiichi Sankyo, Inc.","HERTHENA¿Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy",Not Commenced,,23/01/2023,16/09/2022,Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy,No,Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC),,Yes,,"Adult , Elderly","Female , Male"
17702,2020-005643-22,AG10-304,Interventional studies with investigational medicinal products,"Eidos Therapeutics, Inc.",An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301),Not Commenced,,31/08/2022,16/09/2022,Extension study and safety monitoring of Acoramidis (AG10) in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM),No,Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM),,Yes,,"Adult , Elderly","Female , Male"
17722,2021-003212-11,ITCC-101/APAL2020D,Interventional studies with investigational medicinal products,Princess Máxima Center for Pediatric Oncology,"A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML 
",Not Commenced,,14/09/2022,10/11/2022,A study to evaluate if the addition of venetoclax to chemotherapy (fludarabine/cytarabine/gemtuzumab ozogamicin) improves the survival of children with relapsed acute myeloid leukemia.,Yes,"Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia without FLT3/ITD mutation who are in:
- Second relapse, who are sufficiently fit to undergo another round of intensive chemotherapy
- First relapse who per investigator discretion cannot tolerate additional anthracycline containing chemotherapy. 
",,Yes,,"Under 18 , Adult","Female , Male"
17742,2021-005775-39,INCAGN2385-203,Interventional studies with investigational medicinal products,Incyte Biosciences International Sàrl,"A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti¿LAG-3) and INCAGN02390 (Anti¿TIM-3) as First-Line Treatment in Participants With PD-L1¿Positive (CPS ¿ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck",,,18/04/2023,03/03/2023,"A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385  and INCAGN02390  as First-Line Treatment in Participants  Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck",No,In participants with PD-L1¿positive and systemic therapy¿naive R/M SCCHN.,Yes,,,"Adult , Elderly","Female , Male"
17782,2017-002397-39,20150125,Interventional studies with investigational medicinal products,Amgen Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])",Not Commenced,,18/10/2022,16/12/2022,Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine,Yes,Episodic migraine,,Yes,,Under 18,"Female , Male"
17802,2019-004890-21,NL72427.068.19,Interventional studies with investigational medicinal products,Maastricht University Medical Center+,Effectiveness of Periocular drug Injection in CATaract surgery,Not Commenced,,22/03/2023,14/10/2022,Prevention of macular edema after cataract surgery,No,cystoid macular edema (CME),,Yes,,Elderly,"Female , Male"
17882,2022-000336-28,TAK-341-2001,Interventional studies with investigational medicinal products,"Takeda Development Center Americas, Inc.","A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy",Not Commenced,,10/02/2023,13/02/2023,"A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy",No,Multiple System Atrophy,Yes,,,"Adult , Elderly","Female , Male"
17902,2021-006462-20,CIC-10,Interventional studies with investigational medicinal products,Instituto de Medicina Molecular João Lobo Antunes (iMM),"MESOTHERAPY IN LATERAL EPICONDYLITIS, A RANDOMIZED, DOUBLE- BLIND STUDY TO COMPARE THE EFFICACY OF MESOTHERAPY WITH PIROXICAM AND LIDOCAINE VERSUS INTRADERMAL DRY NEEDLING, IN THE TREATMENT OF LATERAL EPICONDYLITIS.",Not Commenced,,30/11/2022,26/08/2022,"MESOTHERAPY IN LATERAL EPICONDYLITIS, A RANDOMIZED, DOUBLE- BLIND STUDY TO COMPARE THE EFFICACY OF MESOTHERAPY WITH PIROXICAM AND LIDOCAINE VERSUS INTRADERMAL DRY NEEDLING, IN THE TREATMENT OF LATERAL EPICONDYLITIS.",No,lateral epicondylitis,Yes,,,"Adult , Elderly","Female , Male"
17942,2022-000095-18,21656,Interventional studies with investigational medicinal products,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks in women with, or at high risk for developing hormone-receptor positive breast cancer ",,,06/12/2022,26/08/2022,"A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by anti-cancer therapy in women with, or at high risk for developing hormone-receptor positive breast cancer",No,"Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer
",,Yes,,"Adult , Elderly",Female
17962,2022-000434-42,M22-000,Interventional studies with investigational medicinal products,AbbVie Deutschland GmbH & Co. KG,"A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility
Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic
Dermatitis (Flex-Up)",Not Commenced,,08/09/2022,16/09/2022,"This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects
with Moderate to Severe Atopic Dermatitis",No,Moderate to Severe Atopic Dermatitis,,Yes,Yes,Adult,"Female , Male"
17982,2022-000747-77,283PD302,Interventional studies with investigational medicinal products,Biogen Idec Research Limited,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Parkinson¿s Disease and Pathogenic LRRK2 Variants",Not Commenced,,01/02/2023,17/03/2023,A Study to Assess if BIIB122 Tablets are Safe and can Slow Worsening of Early-Stage Parkinson's Disease in Participants with Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale,No,Parkinson's Disease,,Yes,,"Adult , Elderly","Female , Male"
18002,2020-003566-39,NN9500-4656,Interventional studies with investigational medicinal products,Novo Nordisk A/S,"Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial",,,09/03/2023,14/10/2022,Research study on whether a combination of 2 medicines (NNC0194-0499 and semaglutide) works in people with non-alcoholic steatohepatitis (NASH),No,Non-alcoholic steatohepatitis,Yes,,,"Adult , Elderly","Female , Male"
18062,2020-003726-23,1346-0013,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3)",Not Commenced,,03/11/2022,04/11/2022,Clinical trial of  Iclepertin effect on cognition and functional capacity in schizophrenia.,No,schizophrenia,,Yes,,Adult,"Female , Male"
18102,2022-000525-25,61186372NSC3004,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",Not Commenced,,29/12/2022,16/12/2022,A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy,No,EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer ,,Yes,,"Adult , Elderly","Female , Male"
18142,2019-004131-24,67896062CTP3001,Interventional studies with investigational medicinal products,Actelion Pharmaceuticals Ltd.,"A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. 

Macitentan in inoperAble or persistent/reCurrent chronIc ThromboEmbolic Pulmonary Hypertension (MACiTEPH)",Not Commenced,,08/11/2022,16/12/2022,A Phase 3 study to evaluate  whether macitentan 75 mg  is an effective and safe treatment for patients with inoperable or persistent chronic thromboembolic pulmonary hypertension.,No,Chronic thromboembolic pulmonary hypertension,,Yes,,"Adult , Elderly","Female , Male"
18222,2020-001398-59,OSE-127-C201,Interventional studies with investigational medicinal products,OSE Immunotherapeutics,"Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intolerant to previous treatment(s)",,,04/04/2023,14/10/2022,Clinical trial to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with ulcerative colitis who have failed or are intolerant to previous treatment(s),No," Moderate to severe Ulcerative Colitis 
 ",Yes,,,"Adult , Elderly","Female , Male"
18262,2021-003243-21,XL092-303,Interventional studies with investigational medicinal products,"Exelixis, Inc.",A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer,Not Commenced,,19/01/2023,24/02/2023,Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303),No,Metastatic colorectal cancer (CRC),,Yes,,"Adult , Elderly","Female , Male"
18442,2022-002235-60,NN9536-7545,Interventional studies with investigational medicinal products,Novo Nordisk A/S,Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes,Not Commenced,,28/12/2022,24/02/2023,A research study to see how semaglutide helps losing weight in people with excess weight and type 2 diabetes,No,Obesity,,Yes,,"Adult , Elderly","Female , Male"
18502,2022-001387-10,220301,Interventional studies with investigational medicinal products,"Tecnimede - Sociedade Técnico-Medicinal, S.A.                                                       ","A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR)",Not Commenced,,02/01/2023,04/01/2023,A Phase 3 blinded study to assess the efficacy and safety of Favipiravir vs placebo in Non-critical Hospitalized Patients with COVID-19 Pneumonia (PROVIR),No,Coronavirus disease 2019 (COVID-19 pneumonia),,Yes,,"Adult , Elderly","Female , Male"
18522,2022-001088-29,CJDQ443B12201,Interventional studies with investigational medicinal products,Novartis Pharma AG,KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ¿ 1% and an STK11 co-mutation.,Not Commenced,,24/11/2022,02/03/2023,Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ¿ 1% and an STK11 co-mutation.,No,locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ¿ 1% and an STK11 co-mutation,Yes,,,Adult,"Female , Male"
18542,2021-001957-30,CA057-001,Interventional studies with investigational medicinal products,Celgene Corporation,"A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib And Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM)",Not Commenced,,03/01/2023,03/02/2023,A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.,No,Relapsed or Refractory Multiple Myeloma (RRMM) ,,Yes,,"Adult , Elderly","Female , Male"
18562,2021-004732-29,PTG-300-11,Interventional studies with investigational medicinal products,"Protagonist Therapeutics, Inc.",A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera,Not Commenced,,10/03/2023,02/03/2023,A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera,No,Polycythemia Vera,,Yes,,"Adult , Elderly","Female , Male"
18582,2021-001277-23,ARGX-113-2007,Interventional studies with investigational medicinal products,Argenx BV,"A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability,  Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC  in Participants Aged 18 Years and Older With Active Idiopathic  Inflammatory Myopathy
",Not Commenced,,24/02/2023,13/01/2023,A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy ,No,Active Idiopathic Inflammatory Myopathy (IIM),Yes,Yes,,"Adult , Elderly","Female , Male"
18602,2022-001091-34,1305-0014,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A double blind, randomized, placebo-controlled trial evaluating
the efficacy and safety of BI 1015550 over at least 52 weeks in
patients with Idiopathic Pulmonary Fibrosis (IPF)",Not Commenced,,21/12/2022,03/02/2023,"A study to find out whether BI 1015550 improves lung function
in people with Idiopathic Pulmonary Fibrosis (IPF)",No,Idiopathic Pulmonary Fibrosis (IPF),,Yes,,"Adult , Elderly","Female , Male"
18662,2022-001134-11,1305-0023,Interventional studies with investigational medicinal products,"Boehringer Ingelheim, Portugal Lda.                                    ","A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)",Not Commenced,,27/12/2022,16/12/2022,A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs),No,Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs),,Yes,,"Adult , Elderly","Female , Male"
18682,2022-002741-18,GS-US-611-6273,Interventional studies with investigational medicinal products,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression",Not Commenced,,19/10/2022,06/12/2022,A Phase 3 Study for GS-5245 in Participants With COVID-19 Who Have a High Chance of Developing Serious or Severe Disease,No,Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness,,Yes,,"Adult , Elderly","Female , Male"
18722,2021-002905-89,20186,Interventional studies with investigational medicinal products,   Bayer AG                                                                                      ,"An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria",Not Commenced,,17/02/2023,13/01/2023,A study to learn more about how safe the study treatment finerenone is in long-term use when taken with an ACE inhibitor or angiotensin receptor blocker over 18 months of use in children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria,Yes,Treatment of children with chronic kidney disease and proteinuria,,Yes,,"Under 18 , Adult","Female , Male"
18742,2021-000713-17,VX20-121-104,Interventional studies with investigational medicinal products,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis",Not Commenced,,05/01/2023,24/02/2023,A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis,Yes,Cystic Fibrosis ,,Yes,,"Under 18 , Adult","Female , Male"
18762,2021-003314-39,78934804CRD2001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn¿s Disease
",Not Commenced,,31/01/2023,09/02/2023,"Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn¿s Disease
",No,"Moderately to Severely Active Crohn's Disease
",Yes,,,Adult,"Female , Male"
18802,2022-000736-37,1001,Interventional studies with investigational medicinal products,Biotest AG,"A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with moderate or severe COVID-19",Not Commenced,,29/12/2022,03/02/2023,"A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with moderate or severe COVID-19",No,moderate or severe Coronavirus Disease 2019 (COVID-19),,Yes,,"Adult , Elderly","Female , Male"
18882,2021-005528-39,78934804UCO2001,Interventional studies with investigational medicinal products,Janssen-Cilag International N.V.,"A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis

",Not Commenced,,28/03/2023,13/02/2023,Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis,No,"Moderately to Severely Active Ulcerative Colitis
",Yes,,,Adult,"Female , Male"
18902,2022-002222-27,STAR-221,Interventional studies with investigational medicinal products,"Arcus Biosciences, Inc.","A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Loally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.",Not Commenced,,19/04/2023,03/03/2023,"A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body",No,Metastatic Esophageal or Gastric Cancer,,Yes,,"Adult , Elderly","Female , Male"
18942,2020-003571-17,CY6022,Interventional studies with investigational medicinal products,"Cytokinetics, Inc.",An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM).,Not Commenced,,31/03/2023,14/04/2023,This study is performed to collect long term safety and tolerability of aficamten (CK-3773274) on patients with symptomatic hypertrophic cardiomyopathy (HCM),No,symptomatic hypertrophic cardiomyopathy (HCM) ,Yes,,,"Adult , Elderly","Female , Male"
18982,2022-002489-34,AV-APL-B-002-22,Interventional studies with investigational medicinal products,"PharmaMar, S.A.","A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA)",Not Commenced,,03/01/2023,16/12/2022,"A Multicentre, Open label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin versus Control in Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care (NEREIDA)",No,Immunocompromised Adult Patients with Symptomatic COVID-19 requiring Hospital Care ,Yes,,,"Adult , Elderly","Female , Male"
19022,2022-002691-36,CVAY736F12301,Interventional studies with investigational medicinal products,Novartis Pharma AG,"A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)",Not Commenced,,17/04/2023,05/05/2023,Phase 3 study to evaluate two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1),No,Systemic Lupus Erythematosus,,Yes,,"Under 18 , Adult , Elderly","Female , Male"
